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Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of mature B 
lymphocytes in blood, bone marrow and lymphoid tissues. Historically, patients with TP53 
aberration and with refractoriness to chemoimmunotherapy had a dismal prognosis. During the past 
few years a paradigm shift has taken place in the treatment of CLL as new, targeted agents have 
been introduced. 
The aim of this thesis was to explore targeted agents in patients with advanced CLL. 
In the first study, the safety and efficacy of lenalidomide in combination with alemtuzumab was 
explored in a phase I-II trial. The rational was that lenalidomide has its major effects in lymph nodes 
and alemtuzumab in the bone marrow. Furthermore, the capacity of low-dose lenalidomide in 
maintaining immune functions in advanced-phase CLL patients during alemtuzumab treatment was 
evaluated. The combination showed an acceptable safety profile as well as clinical efficacy with an 
overall response rate (ORR) of 58%. Median response duration was 12 months. Lenalidomide had a 
narrow therapeutic dose range, 2.5 mg/day was not efficient, and the maximum tolerated dose was 5 
mg/day. Low-dose lenalidomide increased the frequency of proliferating CD8+ T cells but had no 
effect on the immune checkpoint marker, programmed cell death 1 (PD-1), on T cells. After 
combination treatment, granzyme B+ T cells increased. In conclusion, low-dose lenalidomide and 
alemtuzumab induced major changes in T cells, including increased proliferative activity and 
cytotoxic potential. 
In the second study, the safety and efficacy of ibrutinib in combination with alemtuzumab was 
explored in a phase I trial. The rational was that ibrutinib has its major effects in lymph nodes and 
alemtuzumab in the bone marrow. Further, the toxicity profiles differ. The treatment combination 
was efficient: 7 out of 8 patients responded to treatment and 7 achieved minimal residual disease 
negativity. Within 2 weeks, ibrutinib led to decreased proliferation of CLL cells and T cells. After 4 
weeks of ibrutinib therapy, PD-1 expression was unchanged on T cells. Due to a high rate of 
opportunistic infections, the study was closed in advance and we recommend against the 
combination of ibrutinib and alemtuzumab. 
In the third study, the safety and efficacy of ibrutinib, when used in routine health care, was 
evaluated. Ninety-five consecutive patients, treated in a compassionate use program, were analyzed. 
At a median follow-up of 10 months, the ORR was 84%, the progression free survival (PFS) rate 
was 77% and the overall survival (OS) rate was 83%. PFS and OS were significantly inferior in 
patients with TP53 aberration. Atrial fibrillation occurred in 8% and Richter transformation (RT) 
occurred in 7% of patients. Half of the patients would not have met the inclusion criteria for the 
pivotal study of ibrutinib: this demonstrates the real-world representativity of the patients. The 
observed efficacy and toxicity of ibrutinib in the study were similar to that in pivotal studies.  
In the fourth study, a long-term follow-up of the patients in the compassionate use program for 
ibrutinib was carried out. At 30-month follow-up, the ORR rate was unchanged at 84%, the PFS 
rate was 52% and the OS rate was 63%. Fifty-one percent of patients remained on treatment. In 
contrast to the early (10-month) report, TP53 aberration had no negative survival impact. In 
multivariate analyses, OS was significantly associated with baseline comorbidities and PFS was 
associated with baseline comorbidities and number of prior therapies. Fifty-one percent of the 
patients had grade 3-4 infections and 13% had grade 3-5 opportunistic infections. Fifteen percent 
developed atrial fibrillation. RT occurred in 13%. Twenty-six percent of patients had dose 
reduction or temporary treatment breaks, which had no significant impact on the outcome. Four of 
6 patients who had progressive disease while on ibrutinib were tested for mutation of Bruton’s 
tyrosine kinase. All of them carried the most common mutation leading to ibrutinib resistance. In 
conclusion, ibrutinib was effective and well tolerated for long-term use. The observed efficacy of 
ibrutinib was somewhat inferior to that of pivotal studies. The observed frequencies of treatment 
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1. CHRONIC LYMPHOCYTIC LEUKEMIA 
1.1 Introduction 
Chronic lymphocytic leukemia (CLL) is characterized by a clonal proliferation of mature, 
CD5+ B lymphocytes, which accumulate in blood, bone marrow and lymphoid tissues. The 
disease mostly occurs in elderly patients and the clinical course of CLL is highly variable. 
Chemoimmunotherapy has been the standard first-line treatment for patients with CLL for 
many years [1]. With the advent of novel, targeted agents, the survival of CLL patients has 
improved and the treatment landscape is rapidly changing [2, 3].  
1.2 Epidemiology 
CLL has a high incidence in Europe and North America, intermediate in Africa and low in 
Asia [4]. The incidence of CLL in Sweden is 500 cases/year. Between the years 2000 and 
2015, the prevalence of CLL in Sweden increased from 33/100 000 to 52/100 000 
inhabitants [5]. The increase was due to the improvement of survival of CLL patients [5]. 
More men than women (2:1) are affected [6]. In Sweden, the median age at diagnosis is 71 
years [6].  
1.3 Etiology 
The etiology of CLL is mainly unknown. The most apparent risk factor is age. Incidence is 
higher in persons with a family history of CLL. First-degree relatives of CLL patients have 
8.5-fold elevated risk of developing the disease [7]. A limited number of other independent 
risk factors for CLL have been identified; exposure to pesticides/herbicides and exposure to 
hepatitis C virus have been associated with increased risk. Further, a protective effect of 
sun exposure on CLL risk has been reported [8]. 
1.4 Pathogenesis 
The cell of origin in CLL remains a controversy. However, there is much evidence that the 
first genetic changes in CLL transformation occur at the hematopoetic stem cell stage [9]. 
The disease may be initiated by chromosomal alterations, e.g. del(13q) and trisomy 12. 
During the course of the disease, additional mutations may be acquired, and the leukemia 
becomes more and more aggressive and resistant to treatment. Del(11q) and del(17p) are 
usually acquired at later stages of the disease [10]. 
The activation of normal B cells can be dependent or independent of T helper cells. B 
cells, which are stimulated by T helper cells, will undergo affinity maturation, i.e. 
mutations will be introduced in the heavy chain variable region of immunoglobulin (IGHV) 
gene leading to an increase of the B cell receptor’s (BCR) affinity for the antigen. 
Mutational status is measured by comparing the individual’s IGHV gene to the germline 
sequence of IGHV. CLL with ≤ 98% of the IGHV similar to the germline sequence is 
defined as mutated CLL and CLL with > 98% of the IGHV similar to the germline 
sequence is defined as unmutated CLL. To some extent the mutational status of the IGHV 
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gene reflects the existence of two different disease subtypes [11, 12]. The prevailing model 
implies that CLL with mutated IGHV genes derives from germinal center experienced B 
cells while CLL with unmutated IGHV genes derives from B cells that have differentiated 
in a germinal center independent path.  
1.4.1 Genomic disruptions and gene mutations 
Deletion of the long arm of chromosome 13 is the most frequent cytogenetic aberration in 
CLL occurring in approximately 55% of all patients [13]. Cases with isolated del(13q) have 
a favorable prognosis [13]. Del(13q) leads to down regulation of microRNA 15 and 
microRNA 16 and both microRNAs negatively regulate the anti-apoptotic gene BCL2 (B-
cell lymphoma 2) at the posttranscriptional level, which may lead to increased resistance to 
apoptosis [14].  
Del(11q) is found in about 10% of patients at diagnosis and in up to 25% of patients 
with chemotherapy-refractory disease [15]. It is usually a mono-allelic event and causes the 
loss of the ATM (ataxia telangiectasia-mutated) gene, which encodes ATM, a protein kinase 
that is activated by DNA damage and is an activator of p53 [16]. Thus, ATM works for the 
integrity of the genome. In contrast to patients with TP53 aberration, patients with ATM 
alteration usually respond to chemotherapy [17]. 
Trisomy 12 is detected in 10-20% of CLL patients at diagnosis [13]. The genes behind 
the pathogenesis of CLL with trisomy 12 are largely unknown.  
At diagnosis, 5-15 % of patients have 17p deletion [18]. The TP53 gene is located on the 
short arm of chromosome 17 and deletion of 17p hence leads to a loss of the tumor 
suppressor protein p53. More than 80% of patients with del(17p) also carry an aberration in 
the remaining TP53 allele [19], which implies just as bad a prognostic feature as deletion of 
17p [18]. The terms TP53 aberration and del(17p) can therefore be used interchangeably for 
a clinical purpose. The p53 protein, also known as “the guardian of the genome”, can 
activate DNA repair, hold the cell cycle and initiate apoptosis in response to DNA damage. 
Many chemotherapeutic agents, including alkylating agents and purine analogues rely on 
the pro-apoptotic and antiproliferative effect of p53. The lack of p53 activity results in 
resistance to chemotherapy [20]. TP53 aberration is coupled with higher genomic 
complexity in CLL [21]. Aberration of TP53 predicts a shorter time to progression with the 
novel targeted therapies as well, however the negative impact of TP53 aberration is less 
prominent compared to chemoimmunotherapy [22-25].  
Next generation sequencing (NGS) studies have provided a complete profile of 
mutations in CLL. Studies have shown an adverse prognostic impact of TP53, SF3B1 
(splicing factor 3B subunit 1), MAPK-ERK (mitogen-activated protein kinase - extracellular 
signal-regulated kinase), EGR2 (Early growth response 2), NOTCH1 (Notch homolog1, 
translocation-associated) and BIRC3 (Baculoviral IAP Repeat Containing 3 gene) 
mutations [26-28]. However, TP53 disruption is currently the only mutation affecting the 
treatment choice. 
1.4.2 Heterogeneity and clonal selection 
Many malignancies display intra-tumor-heterogeneity, i.e. genetic differences within one 
single sample. A subclone is defined as a group of cells with a mutation occurring only in 
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fraction of the malignant cells. With NGS technique it has been shown that CLL may be 
composed of heterogeneous malignant cells and that subclonal mutations can affect the 
clinical course of the disease [29]. The prevailing hypothesis is that a small clone of therapy 
resistant cells is present in the beginning of the disease and these resistant cells have an 
advantage of growth during therapy, a process known as clonal evolution [30]. The 
proportion of patients with TP53 disruption increases from 5-15% at diagnosis [18] to 
approximately 40% in fludarabine-refractory patients [31]. In a longitudinal analysis, small 
clones of TP53 mutated cells became the dominant clone at relapse, hence small TP53 
mutated subclones showed the same adverse prognostic impact as clonal TP53 aberrations 
[32].  
1.5 Microenvironment 
CLL cells circulating in the blood are cell-cycle-arrested, while CLL cells located in the 
lymphoid tissue and the bone marrow are activated. CLL cells are subject to spontaneous 
apoptosis when removed from patients, indicating that the malignant cells are addicted to 
the microenvironment for proliferation and survival [33]. The proliferation of CLL cells 
occur within tissue sites known as proliferation centers, which exist in the bone marrow 
and in the lymph nodes. In the proliferation centers, the tumor cells interact with other 
cells: mesenchymal stromal cells (MSC), monocyte-derived nurse-like cells (NLC) and T 
cells [34]. NLCs were first reported as an in vitro phenomenon. NLCs differentiated from 
monocytes when co-cultured with CLL cells [35].  
In CLL-patients, NLCs are found in the spleen and in the lymph nodes. NLCs secrete 
survival signals, including B-cell activating factor (BAFF) and a proliferation-inducing 
ligand (APRIL), which results in higher expression of anti-apoptotic genes in cultured CLL 
cells [36].  
NLCs induce a gene expression profile response in CLL cells with induction of genes 
in the pathways of the BCR and nuclear factor kappa-light-chain-enhancer of activated B 
cells (NFκB) [37]. MSC are found in the secondary lymphatic tissues of CLL patients and 
like the NLCs they secrete survival signals for tumor cells. Further, MSC secrete 
chemokines, of which C-X-C motif chemokine ligand (CXCL)12 is the most important, to 
guide the CLL cells into the tissue, a process known as homing. CLL cells overexpress the 
C-X-C motif chemokine receptor (CXCR)4 that allow the cell to sense and follow the level 
of CXCL12 [38]. 
CLL cells are in close contact with T cells in the microenvironment [34]. T cells can 
either suppress or promote B cell expansion, and their function depends on the activation 
status, T-cell subset, and micro-anatomical location. CD4+ and CD8+ T-cell numbers are 
increased in CLL patients [34]. There is a correlation of T-cell expansion and progressive 
disease [39], but the cause of the T-cell expansion is unknown. The CD8+ T-cell proportion 
is increased relative to the CD4+ T cells, leading to an inversion of the normal CD4:CD8 
ratio [34].  
 Myeloid-derived suppressor cells have recently been identified. They seem to play a 
role in the CLL microenvironment by suppressing T cells and inducing regulatory T cells 
(Treg) [40]. 
 




Figure 1. CLL main pathogenic pathways and target agents against BTK, PI3K and Bcl-2. BCR 
signaling is induced by the recognition of an antigen or by self-binding, Lyn promotes the phosphorylation 
of Igα and Igβ that activates the spleen tyrosine kinase (SYK). SYK then triggers the formation of a multi-
component ‘signalosome’, including BTK, AKT, PI3K and PLCγ2 among others. BCR co-receptor CD19 is 
important for PI3K activation, which recruits and activates PLCγ2, BTK and AKT. These lead to the 
activation of the c-Jun N-terminal kinase (JNK), MEK-extracellular signal-regulated kinase (ERK), 
mammalian target of rapamycin (mTOR) and NF-κB signaling pathways. In addition, CLL cells activate 
these and other prosurvial, activatory pathways by their interaction with many soluble and surface factors. 
As an example: Wnt5a interact with the ROR1/ROR2 dimers promoting the activation of RhoA and Rac-1. 
CXCR4/CXCL12 engagement activates PI3K and downstream pathways, in addition to other molecules. 
The TNF receptors CD40, BAFF-R, TACI and BCMA interact with their ligands CD40L or BAFF and 
APRIL, inducing the activation of the canonical and alternative NF-κB pathways depending on the TNF 
receptor-associated factor (TRAF). NOTCH1 signaling is initiated by the binding with one of the five 
ligands (e.g. jagged 1, Delta-like ligand 1 (DLL1)), followed by the release of the intracellular active portion 
(ICN1), enabling its migration into the nucleus. These pathways lead to the upregulation of anti-apoptotic 
molecules like Bcl-2, Bcl-XL and Mcl-1, sequestering the pro-apoptotic molecules BAX and BAK, and 
inhibiting the intrinsic apoptosis pathway. Inhibitors for PI3K, BTK and Bcl-2 are indicated in red. 
Reprinted in a modified version under the Creative Commons Attribution 4.0 International License, 
http://creativecommons.org/licenses/by/4.0/ from Molecular Medicine 24:9, 2018. Ferrer G and Montserrat E. 
Critical molecular pathways in CLL therapy 
1.6 B cell receptor (BCR) and downstream signaling 
The normal B lymphocyte receives survival and proliferation signals from the 
microenvironment and the BCR is a key factor in this interaction [41]. CLL cells are capable 
of antigen-independent, cell-autonomous BCR signaling [42]. The BCR is composed of a 
membrane bound immunoglobulin bound to Igα and Igβ. BCR pathway signaling is 
activated through the antigenic stimulation of the extracellular domain of the BCR. Upon 
antigen binding, Lck/Yes novel tyrosine kinase (LYN) activates the immunoreceptor 
tyrosine-based activation motifs (ITAMs) on the cytoplasmic parts of Igα and Igβ. Next, 
spleen tyrosine kinase (SYK) initiates the formation of a “signalosome” including Bruton’s 
tyrosine kinase (BTK), phosphatidyl-inositol 3-kinase (PI3K), anti-apoptotic protein kinase 
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(AKT) and phospholipase C gamma 2 (PLCγ2). This leads to activation of downstream 
kinases including mammalian target of rapamycin (mTOR) and NFκB (Figure 1). These 
events ultimately lead to a change in gene expression promoting survival and proliferation.  
1.7 Diagnosis, clinical staging and manifestations 
1.7.1 Diagnosis 
According to the World Health Organization (WHO), classification the CLL diagnosis 
requires a circulating clonal B lymphocyte count of at least 5 x 109 cells/L. The CLL cells 
are morphologically mature and they express B-cell markers (CD23, CD19 and low CD20) 
and CD5 [43]. 
Small lymphocytic lymphoma (SLL) is defined as lymphadenopathy and/or 
splenomegaly and a count of less than 5 x 109/L CLL cells in the peripheral blood and the 
absence of cytopenia caused by clonal marrow infiltration. In the absence of 
extramedullary disease, a clonal B lymphocyte count of less than 5 x 109/L is classified as 
“monoclonal B-cell lymphocytosis” (MBL) [43]. MBL is classified into low-count MBL 
(< 0.5x109 cells/L) and high-count MBL (≥ 0.5x109 cells/L). Low-count MBL has an 
extremely low risk of progression and monitoring is not recommended, while high-count 
MBL has a 1-2 percent yearly risk for progression to CLL or SLL requiring treatment [44]. 
1.7.2 Clinical staging 
CLL has an extremely heterogeneous clinical course and therefore staging systems are 
helpful to facilitate management of patients. The most commonly used methods for 
predicting survival in CLL are the two similar staging systems: Rai [45] and Binet [46]. They 
are based on a clinical examination of lymph nodes, liver and spleen and the presence of 
thrombocytopenia and/or anemia. However, these staging systems do not fully reflect the 
heterogeneity of CLL since they do not take genetic and chromosomal characteristics into 
account. Several attempts have been made to improve prognostic models for CLL. 
As cytogenetic techniques have developed, so has the information regarding prognostic 
factors. With the fluorescence in situ hybridization (FISH) technique, chromosomal 
disruptions in CLL and their prognostic implications have been explored. Patients with 13q 
deletion have the longest overall survival (OS) (median survival 133 months from the time 
of diagnosis). Trisomy 12 and normal karyotype carry intermediate risk [13]. Patients with 
deletion of 17p have the poorest prognosis (median survival of 32 months from the time of 
diagnosis) followed by 11q deletion (median survival 79 months from the time of 
diagnosis) [13].  
Survival is shorter for patients with unmutated IGHV genes regardless of disease stage. 
Median survival for patients with low Binet stage and unmutated IGHV was 95 months 
compared with 293 months for patients with mutated IGHV [11].   
Recently a new prognostic index for treatment-naive patients was developed, the CLL 
International Prognostic Index (CLL-IPI), which includes five independent prognostic 
factors [47]. The CLL-IPI is based on TP53 status (no abnormalities vs TP53 disruption), 
IGHV mutational status (mutated vs unmutated), beta2-microglobulin 
(≤  3.5 mg/L vs > 3.5 mg/L), clinical stage (Binet A or Rai 0 vs Binet B-C or Rai I-IV) and 
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age (≤ 65 years vs > 65 years). CLL-IPI identifies four risk groups showing different 5-year 
OS: low, intermediate, high and very high risk. The 5-year OS rate in the low risk group 
was 93% and in the very high risk group 23%. TP53 disruption was the most important risk 
factor and patients with 17p deletion/TP53 aberration always fell into the high or very high 
risk group. The CLL-IPI has not been validated in the era of new, targeted treatment.  
1.7.3 Manifestations 
Common symptoms of CLL include lymphadenopathy, hepatosplenomegaly, constitutional 
symptoms and cytopenia related to bone marrow infiltration. Patients may also suffer from 
infections, autoimmune hemolysis and transformation to high-grade lymphoma/Richter 
transformation (RT) [48]. 
 
Autoimmune complications 
CLL is often complicated by autoimmune cytopenia. The most frequent autoimmune 
complication is autoimmune hemolytic anemia (AIHA) with an incidence of 5-10%, 
followed by immune thrombocytopenia (ITP) in 1-2 % of patients. Pure red cell aplasia and 
autoimmune neutropenia are unusual events [49]. AIHA is more frequent in patients with 
unmutated IGHV, with del(17p) and del(11q) and in heavily pretreated patients [50]. In both 
AIHA and ITP it is assumed that non-malignant B cells produce the autoantibodies since 
the antibodies are polyclonal [49]. Fludarabine monotherapy has a well-known association 
with autoimmune cytopenia [51]. When fludarabine is given in combination with rituximab 
the incidence of autoimmune cytopenia does not differ from the incidence in the general 
CLL population [52]. Compared to chemotherapy, triggering of autoimmune cytopenia is 
less common with novel targeted treatment [53]. If no other CLL symptoms are present, the 
first-line treatment for autoimmune cytopenia is corticosteroids [53]. 
 
Immune defects and infections 
Infections account for 25-50% of deaths in patients with CLL [54]. Several factors have been 
reported to increase the susceptibility to infection; hypogammaglobulinemia, T-cell defects, 
natural killer (NK)-cell defects, neutropenia and defects in complement activation [55]. 
Further, the infection rate increases with duration of disease, with advanced stages and with 
CLL treatment [54].  
Hypogammaglobulinemia is the most common immune defect with up to 85% of 
patients being affected [56]. Randomized trials conducted in the 1980s found that 
prophylactic immunoglobulin substitution decreased the rate of bacterial infections in CLL 
patients with hypogammaglobulinemia and recurrent bacterial infections, but there was no 
effect on survival [56]. The prophylactic use of immunoglobulin substitution is usually 
recommended in patients with severe hypogammaglobulinemia and recurrent bacterial 
infections [48, 57]. Vaccination against pneumococcus and the seasonal influenza are 
recommended for CLL patients [58], but the response to the vaccines might be inefficient 
[56]. Vaccination in the beginning of the disease course, before aggravation of 
hypogammaglobulinemia, can be beneficial [56]. The mechanism behind the development of 
hypogammaglobulinemia is not completely understood.  
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T-cell dysfunction is due to several factors, such as defective immunological synapse 
formation, impaired cell cytotoxicity and imbalance in cell subsets. T-cell activation 
through the T cell receptor (TCR) is regulated by co-stimulatory and inhibitory signals, 
including immune checkpoint receptors. In particular, the immune checkpoint receptor 
programmed cell death 1 (PD-1) is induced on activated T cells, and when bound to the 
ligand, programmed death-ligand 1 (PD-L1), expressed on tumor cells or cells in the tumor 
microenvironment, TCR signaling is reduced [59]. T cells, which have impaired effector 
functions due to chronic antigen stimulation, have an increased PD-1 expression and can be 
defined as “exhausted”. T cells in CLL patients displayed a high PD-1 expression [60-62]. 
In CLL, NK cells are defect with a lack of cytoplasmatic granules and a reduced ability 
of killing tumor cells [63]. It is largely unknown how the CLL cells cause the defect in NK 
cells. The size of the NK-cell compartment relative to the size of the CLL clone was 
significantly higher in CLL patients with lower stage disease and with mutated IGHV [64]. 
 
Richter transformation 
Richter transformation is the development of a secondary aggressive lymphoma in the 
setting of underlying CLL. Two pathologic variants of these transformations are 
recognized: diffuse large B cell lymphoma (DLBCL) (90%) and more rarely Hodgkin 
lymphoma (10%) [65]. RT occurs at a median time of 2 years after diagnosis [65]. The clinical 
course is usually aggressive, and the prognosis is dismal. There are two major categories of 
RT − RT that is clonally related to the underlying CLL and RT that is unrelated to the 
underlying disease [66]. Clonally unrelated cases, which account for approximately 10% of 
cases, have a much better prognosis than clonally related [65]. The incidence rate of RT is 
estimated at 0.6% per year [67]. Patients treated with rituximab in combination with FC had 
a lower incidence rate, compared to patients treated without the addition of rituximab [65]. 
The rate of transformation in patients treated with ibrutinib, idelalisib or venetoclax seems 
to be the same as for historical controls treated with chemoimmunotherapy [65]; however, 
the follow-up time for the novel agents is limited.  
The majority of patients with RT have unmutated IGHV. Further, the presence of 
adverse genomic disruptions and lymph nodes > 3 cm were correlated to RT [68]. R-CHOP 
(rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) is the most 
commonly used treatment for RT, but survival usually does not exceed 12 months [69]. In 
young patients (< 60 years), autologous or allogeneic hematopoetic stem cell 
transplantation (HSCT) can be effective, according to a retrospective study by the 
European Group for Blood and Marrow Transplantation (EBMT). At a follow-up of 3 
years, the progression free survival (PFS) after autologous HSCT was 45%, but there was 
no plateau in the survival-curve. The PFS at 3 years after allogeneic HSCT was 27% [70].  
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2 TREATMENT OF CLL 
2.1 Treatment indications 
Until now, only patients with symptomatic disease require therapy [71]. Eighty-five percent 
of patients do not require treatment at the time of diagnosis [6] and they should be subject to 
“watch and wait”. Before treatment is initiated there should be signs of active disease i.e. 
the presence of cytopenia due to bone marrow failure, splenomegaly, hepatomegaly, 
symptomatic lymphadenopathy, a rapid doubling of the lymphocyte counts (< 6 months) or 
occurrence of constitutional symptoms (fatigue, fever, weight loss, night sweats). The 
lymphocyte count should not be the only criterion for initiation of treatment [48]. 
Several randomized trials showed no benefit of early treatment with chemotherapy [71]. 
Recent data indicate that ibrutinib prolongs PFS of patients with untreated, early stage CLL 
with increased risk of progression [72]. However, no survival data have been reported and 
follow-up time is short, therefore it is still unknown if indication for treatment will change 
in the era of new, targeted agents.  
2.2 Treatment evaluation and minimal residual disease (MRD) 
The treatment response is evaluated using the International Workshop on CLL (IWCLL) 
criteria [48]. Partial remission (PR) requires > 50% reduction of lymphocytosis and lymph 
node size. Complete remission (CR) requires absence of lymphadenopathy, 
hepatosplenomegaly, cytopenia and a lymphocyte count < 4 x 109/L. In clinical trials, a 
bone marrow biopsy with less than 30% of nucleated cells being lymphocytes is required 
for CR. The tyrosine kinase inhibitors redistribute CLL cells from lymph nodes to the 
peripheral blood. As a consequence, the response criteria have been slightly modified 
introducing the concept of PR with lymphocytosis (PR-L), which is considered a response 
to such a treatment [73]. Progressive disease (PD) is defined as > 50% increase of lymph 
node size, > 50% increase of lymphocytes or a significant decrease of hemoglobin or 
platelet count from baseline. Stable disease (SD) is defined as absence of PD and failure to 
achieve at least a PR. Patients not achieving at least PR or relapsing within 6 months after 
treatment initiation are classified as refractory to treatment. Relapse is classified as disease 
progression in a patient who previously achieved a response to treatment for 6 months or 
more [48]. 
Minimal residual disease (MRD) negativity is defined as less than 1 CLL cell/10 000 
leukocytes, measured by flow cytometry. MRD negativity independently predicts for 
longer PFS and OS in patients receiving chemoimmunotherapy in the frontline setting [74]. 
Recent data suggest that MRD negativity is prognostic also for venetoclax treatment [75]. 
The prognostic value of MRD negativity for tyrosine kinase inhibitors is unknown. MRD is 
not routinely measured in clinical practice, however many trials assess MRD level as an 
end-point. 
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2.3 Cytostatic agents 
For decades, the only available agents with effect in CLL were the alkylating agents, 
chlorambucil and cyclophosphamide, which alkylate and cross-link DNA resulting in p53-
dependent stress and apoptosis. Monotherapy with chlorambucil was the most frequent 
treatment [71]. Chlorambucil has low toxicity and cost, but low overall response rate (ORR) 
of 30-72% and CR 0-7% as well as short PFS of 8-18 months [76]. Chlorambucil did not 
prolong OS but might be used for symptom control [77, 78].  
Bendamustine differs structurally from other alkylators by its benzimidazole ring. The 
drug appears to cause more extensive and more long-lasting DNA-breaks [79]. 
Bendamustine as monotherapy was found to yield higher ORR and longer PFS when 
compared to chlorambucil, but there was no significant difference in OS [80].  
Fludarabine is a purine analog, which inhibits DNA polymerase and ribonucleotide 
reductase. In the 1980s, it was shown that purine analogues more frequently achieved CR 
than alkylator-based regimens [81]. However, fludarabine as monotherapy did not improved 
OS [82]. Fludarabine and cyclophosphamide in combination was well tolerated and 
improved PFS compared to fludarabine as monotherapy [83].  
2.4 Monoclonal antibodies 
2.4.1 Anti-CD20: rituximab, ofatumumab and obinutuzumab 
The CD20 antigen is expressed on the surface of B lymphocytes. The anti-CD20 
monoclonal antibodies (mAbs) bind to the CD20 antigen and activate antibody-dependent 
cellular cytotoxicity (ADCC) and/or complement-dependent cytotoxicity (CDC) towards 
the B lymphocyte. Combinations of CD20 mAbs with chemotherapy or targeted agents are 
very effective treatments for CLL (see below) and CD20 mAbs are rarely used as 
monotherapy.  
Based on their mechanisms of action, CD20 mAbs are grouped into type I and type II. 
Rituximab and ofatumumab are of type I; they induce both ADCC and CDC [84]. 
Ofatumumab targets a different epitope on the CD20 molecule and shows stronger affinity 
than rituximab [84]. In a pivotal study, ofatumumab alone induced a response in 43-49% of 
relapsed/refractory CLL patients, but the median time to disease progression was only 4.6-
5.5 months [85]. In 2019, the European Medicines Agency (EMA) withdrew ofatumumab 
from the market at the request of the marketing authorization holder.  
Obinutuzumab is a humanized, glycoengineered type II anti-CD20 mAb; it induces 
only ADCC but no CDC [84]. The glycosylation increases the activation of NK cells [86]. 
Obinutuzumab as monotherapy has proven to be an active drug for CLL with a median PFS 
of 10.7 months in relapsed/refractory patients [87]. 
2.4.2 Anti-CD52: alemtuzumab 
Alemtuzumab is a humanized mAb directed against CD52, which is expressed by normal 
as well as malignant B and T lymphocytes. Important effector mechanisms for 
alemtuzumab are CDC and ADCC [88]. Alemtuzumab induced an ORR of 30-40 % and a 
median PFS ranging from 9-15 months in relapsed/refractory CLL patients [88, 89]. 
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Alemtuzumab is effective in patients with high-risk genetic markers such as 17p deletion 
[90] and the drug was previously considered the standard treatment of relapsed/refractory 
CLL patients. The main effect of alemtuzumab is in blood and bone marrow and its 
effectiveness in CLL with bulky lymphadenopathy is limited [89]. Alemtuzumab depletes 
immune cells leading to an increased risk of infections, including opportunistic infections, 
in particular cytomegalovirus (CMV) reactivation [91]. Alemtuzumab was withdrawn from 
the market in 2012 but is available through a free compassionate use program. Since the 
introduction of the novel, targeted agents, the use of alemtuzumab for CLL is very limited. 
2.5 Chemoimmunotherapy  
Until recently, a combination of fludarabine, cyclophosphamide and rituximab (FCR) was 
the gold standard frontline treatment regimen in most CLL patients younger than 65 years 
and without TP53 aberration. FCR has shown ORR of 90%, CR rates of 44% and 
prolonged survival in CLL patients treated first-line [1]. As previously mentioned, patients 
with TP53 disruption are refractory to this treatment. Before the era of new, targeted 
agents, patients relapsing after FCR had a dismal prognosis with median OS of 51 months 
[92].  
A follow-up of 300 consecutive patients treated with first-line FCR (FCR300 trial) 
showed a median PFS of 6.4 years and a median OS of 12.7 years. At 13 years follow-up 
the PFS for mutated patients was 54 % and the PFS for unmutated patients was 8.7%. For 
patients with mutated IGHV there was a plateau on the PFS curve with no relapses beyond 
10.4 years, implying that more than half of IGHV mutated patients had a long remission or 
cure with FCR [93]. These results were confirmed in a long-term follow-up of the CLL8-trial 
in which 408 patients treated with first-line FCR showed a median PFS of 4.7 years. At 5 
years patients with mutated IGHV had a superior PFS rate compared to patients with 
unmutated IGHV (67% vs 36%) [94]. 
However, fludarabine-based regimens are not always easily tolerated. 
Myelosuppression with prolonged neutropenia and infections are common [1]. Also, 
approximately 5% of patients develop secondary acute myeloid leukemia/myelodysplastic 
syndrome after FCR treatment [93, 95].  
Results from a randomized comparison between FCR and bendamustine-rituximab 
(BR) in previously untreated patients showed that patients treated with BR had a 
significantly shorter PFS and to a less extent achieved CR as well as MRD negativity [96]. 
However, in elderly (> 65 years) patients there was no significant difference in PFS 
between FCR and BR after a median follow-up time of 3 years. Further, treatment toxicities 
such as neutropenia and infections were more pronounced in elderly patients [96]. This study 
led to the recommendation of BR to the majority of patients older than 65 years in Sweden 
[58].  
In the phase 3 CLL11-trial, 781 treatment-naive patients with comorbidities were 
randomized to chlorambucil as monotherapy or in combination with either obinutuzumab 
or rituximab. Patients receiving obinutuzumab-chlorambucil had a longer PFS compared to 
those treated with rituximab-chlorambucil (median PFS 27 months vs 16 months) [97]. 
Further, the proportion of patients reaching MRD negativity was significantly higher with 
obinutuzumab treatment (20% in the obinutuzumab-chlorambucil arm vs 3% in the 
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rituximab-chlorambucil arm). However, infusion-related reactions were significantly more 
frequent with obinutuzumab. The CLL11-trial established the combination of 
obinutuzumab-chlorambucil as first-line therapy for “unfit” patients [97]. 
2.6 Bruton’s tyrosine kinase (BTK) inhibitors 
2.6.1 Ibrutinib 
Ibrutinib is an oral, selective and irreversible inhibitor of BTK, a non-receptor tyrosine 
kinase that plays a critical role in the BCR signaling. The BTK gene was discovered in 
1993 [98]and is named after Ogden Bruton, who described X-linked agammaglobulinemia 
(XLA) in 1952 [99]. Mutations in the BTK gene can cause XLA, a genetic disorder 
characterized by the lack of mature B cells and profound lack of immunoglobulins [100]. 
Ibrutinib binds covalently to the cysteine-481 (C481) amino acid of the BTK enzyme and 
thus inhibits the BCR signaling pathway [101] (Figure 1). In addition, BTK inhibition also 
leads to decreased CXCR4 surface expression and as a consequence, CLL cells are 
redistributed into the blood with rapid resolution of lymphadenopathy [102]. Among the 
majority of patients, the lymphocytosis resolved within 8 months, but prolonged 
lymphocytosis was not a sign of suboptimal response to therapy [103].  
Ibrutinib is given orally once daily at a fixed dose of 420 mg and the treatment is 
continuous. After 4 hours of administration, the drug gives a complete occupancy of the 
active site of the BTK and the full occupancy is maintained for at least 24 hours. Ibrutinib 
is mainly metabolized by cytochrome P450 (CYP)3A4 and the use of strong CYP3A 
inhibitors increases ibrutinib exposure 20-fold [104]. Therefore, strong CYP3A 
inducers/inhibitors should be avoided. No dose adjustment is required in patients with 
moderate renal impairment since ibrutinib is mainly eliminated via faeces.  
In addition to BTK, ibrutinib inhibits other tyrosine kinases including interleukin-2-
inducible T cell kinase (ITK), endothelial growth factor receptor (EGFR), tyrosine kinase 
expressed in hepatocellular carcinoma (TEC) and bone marrow tyrosine kinase on 
chromosome X (BMX). Thus, ibrutinib has significant off-target effects. 
The first phase 2 study (PCYC-1102) of ibrutinib included treatment-naive as well as 
pretreated CLL patients. The relapsed/refractory group included 85 patients of which 89% 
responded to treatment. The response was independent of risk factors including TP53 
disruption and IGHV mutation [105]. A 5-year follow-up of PCYC-1102, which included 
patients who continued in an extension study (PCYC-1103), showed that the CR rate was 
modest in relapsed/refractory patients (10%). The median PFS in relapsed/refractory 
patients was 51 months, which is almost ten times longer than with previous standard of 
care salvage regimens such as ofatumumab [85]. The median OS was not reached. TP53 
disruption was an independent prognostic factor for inferior PFS and OS, patients with 
TP53 disruption had a median PFS of 26 months and a median OS of 57 months. Outcome 
did not differ significantly between patients with mutated IGHV and unmutated IGHV. 
Complex karyotype (≥ 3 unrelated chromosomal abnormalities) was not established as an 
independent prognostic factor since the outcome was heavily influenced by the coexistence 
of TP53 disruption [23]. However, this contrasted with another ibrutinib study that reported 
complex karyotype to be a stronger driver for treatment failure than TP53 disruption [106].  
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In the pivotal phase 3 study (RESONATE), patients with previously treated CLL were 
randomized between continuous ibrutinib and fixed duration (24 weeks) ofatumumab [2]. 
The ORR in the ibrutinib arm was 91% and 11% of patients reached CR. Median PFS was 
significantly longer with ibrutinib than with ofatumumab (44 months vs 8.1 months). The 
PFS benefit with ibrutinib was preserved in the high-risk group (i.e. patients with TP53 
disruption, del(11q) and/or unmutated IGHV), which represented 82% of the patients [2, 107]. 
Median PFS in patients with del(17p) and/or TP53 aberration was 41 months compared to 
57 months for patients without del(17p)/TP53 aberration. However, the difference was not 
statistically significant. The low number of patients in the subgroups was a limiting factor 
in the analysis. The median OS was 68 months in the ibrutinib arm, which was significantly 
longer than OS in the ofatumumab arm [107]. The RESONATE study led to Food and Drug 
Administration (FDA) and EMA approval of ibrutinib in the second line setting.  
Discontinuation of ibrutinib therapy has been a matter of concern. In a 3-year follow-
up of the phase 2 trial PCYC-1102/1103, 19% of treatment-naive patients and 48% of 
previously treated patients discontinued treatment. Toxicity was the reason for 11% of 
patients [108]. In the 6-year follow-up of RESONATE, 78% discontinued treatment. Sixteen 
percent discontinued due to toxicity. The probability of ibrutinib discontinuation for non-
relapse reasons has been reported to increase by 10 percentage points for each addition of 
prior therapy [109].  
In summary, the abovementioned clinical trials in (mostly) relapsed/refractory patients 
reported an ORR to ibrutinib of approximately 90% with a modest CR rate of 
approximately 10%. The median PFS was 51 months in PCYC-1102/1103 and 44 months 
in RESONATE. IGHV status had no impact on survival time. Patients with TP53 
aberration had a shorter PFS and OS, however in the RESONATE trial the difference was 
not significant. Several other clinical trials have explored ibrutinib in patients with TP53 
aberration [110, 111]. A cross study analysis of the 230 patients with relapsed/refractory CLL 
and TP53 aberration from 3 clinical studies (PCYC-1102/1103, RESONATE and 
RESONATE-17) showed 30-month PFS at 57% and OS at 69%, respectively [112].  
Ibrutinib is generally well tolerated, even by elderly patients with comorbidities. Atrial 
fibrillation is a well-known side effect with ibrutinib with a reported incidence of 6-16% in 
clinical trials [2, 108, 110, 113-115]. Furthermore, the FDA reported ventricular arrhythmias in 
0.2% of ibrutinib-treated patients [116]. Cardiac tissue expresses BTK, but it is not known if 
the suppression of BTK or other off-target kinases causes the arrhythmias. Another 
ibrutinib-associated adverse event is bleeding; mild bleedings have been reported in more 
than 50% of patients and major hemorrhages (≥ grade 3) in 8-9% [23, 108]. Bleedings are 
reported with the more selective, second-generation BTK inhibitors as well [117], implying 
platelet dysfunction induced by BTK inhibition. Rash and diarrhea are related to EGFR 
inhibition but tend to be resolved with time. Hypertension has been reported as a side effect 
of ibrutinib in up to 72% of patients [118]. In the case of adverse events, dose reduction of 
ibrutinib does not seem to mitigate the treatment efficacy [119-121].  
As previously mentioned, the susceptibility to infections is increased in patients with 
CLL. In CLL patients treated with ibrutinib, overall rates of infections are 10-15% in the 
first-line setting and 30-50% in relapsed disease [54]. There are several reports of 
opportunistic infections such as Aspergillus, Cryptococcus and Pneumocystis jiroveci 
pneumonia (PJP) during ibrutinib treatment [122-124]. BTK is an important activator of 
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macrophages and it has been suggested that BTK is needed for control of Aspergillus 
infection [125]. Moreover, BTK mediates pathways of immune response in neutrophils and 
monocytes [126]. A retrospective study of 560 patients reported a cumulative incidence of 
opportunistic infection at 4.7% after 5 years of treatment [127]. Invasive aspergillosis was the 
most frequent opportunistic infection and no case of PJP occurred. In a study of ibrutinib 
for primary central nervous system lymphoma, an incidence of Aspergillus infection of 
39% was reported [125]. Ibrutinib has been reported to have an immunomodulating effect 
caused by the inhibition of BTK and ITK. PD-1 expression was markedly reduced during 
ibrutinib treatment [128, 129]. Regarding effects on T cell numbers, studies have reported 
disparate results [128, 129]. 
To date, it is unclear which is the most important reason for the infections seen during 
ibrutinib treatment. Reasons might be CLL, previous treatment or BTK inhibition. 
However, the infection risk is not increased when compared to treatment with alkylator-
based regimens or CD20-mAbs [54].  
Ibrutinib has indeed changed the treatment landscape for CLL and is now approved by 
the FDA and the EMA for all lines of treatment. However, ibrutinib resistance is a growing 
concern as more patients receive this treatment. One of the main mechanisms for acquired 
resistance is the development and selection of resistant clones. The most frequently 
described mutation leading to ibrutinib resistance is BTK cysteine to serine (C481S) 
mutation, resulting in a reversible binding of ibrutinib. The second most common mutation 
is a gain-of-function mutation in PLCγ2, resulting in autonomous BCR activity [130]. In 
ibrutinib-treated patients with PD, mutations in BTK or PLCγ2 were detected in 85% of 
patients and these mutations were detected at a median of 9.3 months before relapse [130]. In 
a French retrospective study, 30% of patients, who had been treated with ibrutinib for 3 
years, had a BTK- and/or a PLCγ2-mutation [131]. The mutations were significantly 
associated with subsequent CLL progression. 
 
Real-world data for ibrutinib 
“Real-world evidence” can be defined as information on health care that is derived from 
sources outside research settings [132]. Clinical trials are often conducted in selected 
populations that differ from patients in routine health care. An American real-world study 
included 616 ibrutinib-treated CLL patients, 88% from routine clinical practice and 12% 
from clinical trials. Eighty-seven percent of patients were previously treated. Thirty-nine 
percent had TP53 aberration. The median PFS was 35 months and the median OS was not 
reached. There was no significant difference of PFS in first-line patients compared to PFS 
in previously treated patients. Further, there was no significant difference between 
outcomes for patients in routine clinical practice compared to those in clinical studies. In 
this real-world study, deletion of 17p had no significant impact on the outcome. However, 
complex karyotype predicted for shorter survival [133]. A Danish real-world study of 205 
CLL patients reported 24-month PFS at 72%. Nineteen percent received ibrutinib as first-
line and 75% had TP53 aberration. [134]. In our Swedish real-world study, a median PFS of 
37 months was reported [135]. Thus, the reported PFS times in the real-world studies are 
shorter than that previously described in the pivotal phase 3 study (RESONATE) with a 
median PFS of 44 months [107]. As previously mentioned, 27% of patients in RESONATE 
had TP53 aberration [112] and in the cross study including only previously treated CLL 
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patients with TP53 aberration, the reported PFS was similar to real-world results [112]. Thus, 
the perceived difference in outcome between the patients treated in routine clinical practice 
and those in clinical studies seems to be, at least partly, explained by the occurrence of 
TP53 aberration. 
At a median follow-up of 17 months in the abovementioned American real-world 
study, 41% of patients discontinued ibrutinib treatment. Twenty-one percent of patients 
discontinued treatment due to intolerance [133]. Another American real-world study included 
1497 CLL patients who were treated with ibrutinib first-line. This study reported 16% 
discontinuation rate at 6 months [136]. The Danish real-world study reported that 42% of 
patients had discontinued their treatment at 21 months [134]. At 30-month follow-up of our 
real-world ibrutinib study, 49% of patients had discontinued treatment. Toxicity was the 
reason for 20% [121]. At 45-month follow-up, 63% had discontinued treatment [135]. In 
summary, real-world studies reported higher rates of discontinuation when compared to 
clinical trials, and in particular higher rates of discontinuation due to toxicity [108].  
The American retrospective study reported that, at 17-month follow-up, 19% of 
patients required dose reduction due to adverse events. In our real-world ibrutinib study, 
26% of patients required dose reduction at 30-month follow-up. In the clinical phase 2 
study PCYC-1102/1103, 10% of patients required dose reduction at 36-month follow-
up [108]. Thus, dose reductions seemed to be more frequent in routine health care than in 
clinical trials. 
 
Phase 3 trials comparing ibrutinib with chemotherapy/chemoimmunotherapy 
In a phase 3 study (RESONATE-2), previously untreated CLL patients, 65 years or older, 
without TP53 disruption, were randomized to ibrutinib or chlorambucil. The ORR in the 
ibrutinib arm was 92%. CR rate increased from 11% at 18-month follow-up to 30% at 5-
year follow-up. At a median of 5-year follow-up, the PFS in the ibrutinib group was 70% 
compared to 12% in the chlorambucil group. Five-year OS favored ibrutinib (83%) over 
chlorambucil (68%), despite 57% of patients in the chlorambucil group crossing over to 
ibrutinib [137]. These results demonstrated the improved survival with ibrutinib compared to 
chlorambucil first-line and ibrutinib monotherapy was established as an option for 
treatment-naive, elderly (≥ 65 years) CLL patients.  
The ECOG1912 trial compared ibrutinib-rituximab with FCR, which was the previous 
gold standard for young, fit patients. At a median of 4 years follow-up, ibrutinib-rituximab 
improved PFS significantly for patients with unmutated IGHV. In those with mutated 
IGHV, the small improvement observed with ibrutinib-rituximab was not significant [138, 
139]. A longer follow-up time is needed for patients with IGHV mutation considering their 
excellent long-term response to FCR. 
In the Alliance trial, treatment-naive patients over 65 years were randomized to 
ibrutinib or ibrutinib-rituximab or BR. Both ibrutinib-containing regimens yielded superior 
PFS compared to chemoimmunotherapy regardless of cytogenetic features. However, there 
was no significant difference in OS. CR rates and MRD rates were modest in the ibrutinib 
arm; 7% reached CR and 1% reached MRD negativity. The addition of rituximab to 
ibrutinib did not impact PFS or OS [140].  
In the Illuminate trial, ibrutinib-obinutuzumab was tested against chlorambucil-
obinutuzumab in elderly and comorbid patients [141]. Ibrutinib-obinutuzumab showed a 
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significant PFS-increase. However, it was unclear if it is beneficial to add obinutuzumab to 
ibrutinib. 
In summary, three phase 3 studies confirmed the superiority of ibrutinib compared to 
chemoimmunotherapy for all subgroups except for patients with mutated IGHV. For 
patients with mutated IGHV, the optimal front-line treatment is still not known.  
2.6.2 Second-generation BTK inhibitors: acalabrutinib and zanubrutinib 
The second-generation BTK inhibitors, acalabrutinib and zanubrutinib have higher 
selectivity for BTK compared to ibrutinib and they have shown promising early results and 
possibly also an improved toxicity profile [142, 143]. Like ibrutinib, they bind irreversibly and 
covalently to C481 and thus, do not overcome common mechanisms of ibrutinib resistance. 
However, they may be useful in ibrutinib-intolerant patients [144].  
In a phase 2 trial, relapsed/refractory CLL patients were treated with acalabrutinib and PFS 
at 45 months was 58%. Thirteen percent of patients discontinued treatment and 7% showed 
atrial fibrillation [145].  
In a phase 3 trial, previously untreated CLL patients were randomized to acalabrutinib-
obinutuzumab or acalabrutinib as monotherapy or chlorambucil-obinutuzumab. The 28-
month interim results have recently been reported with a significantly improved PFS in 
both acalabrutinib arms. PFS rates for acalabrutinib-obinutuzumab, acalabrutinib as 
monotherapy and chlorambucil-obinutuzumab and were 93%, 87% and 47% respectively. 
Acalabrutinib was well tolerated; the incidence rates of atrial fibrillation were 3% and 4% 
in the acalabrutinib arms and 1% in the chlorambucil arm. The incidence rates of 
hypertension, grade 3 or higher, were not increased in the acalabrutinib arms. However, 
bleeding of all grades was more frequent in the acalabrutinib arms (43, 39% vs 12%). Thus, 
preliminary results report that acalabrutinib was efficient in treatment-naive CLL patients. 
The toxicity profile was acceptable with less cardiac toxicity than for ibrutinib [117], but with 
similar rate of bleeding toxicity. A phase 3 trial of acalabrutinib vs ibrutinib in previously 
treated CLL patients is ongoing (NCT02477696). Acalabrutinib is approved by the FDA 
for CLL treatment.   
Zanubrutinib demonstrated less selectivity for BTK compared to acalabrutinib [146]. In a 
phase 1 study, no patient progressed, at 12 months. Zanubrutinib demonstrated a low rate 
of major toxicities [143]. A phase 3 trial on zanubrutinib vs ibrutinib in previously treated 
CLL patients is ongoing [147]. Zanubrutinib was recently approved by the FDA for treatment 
of mantle cell lymphoma. 
2.7 Phosphatidyl-inositol 3-kinase (PI3K) inhibitors 
2.7.1 Idelalisib 
PI3Ks are enzymes involved in many cellular processes including cell survival, 
proliferation and differentiation. The PI3Ks are divided into four classes (I-IV) and class I 
is subdivided into four isoforms: alpha, beta, delta and gamma. PI3Kδ has a critical role in 
the BCR pathway mediating survival, proliferation, migration and adhesion [148].  
Idelalisib is an oral inhibitor of the delta isoform of PI3K (Figure 1) and it was 
investigated in a randomized phase 3 trial using rituximab in combination with either 
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idelalisib or placebo in relapsed CLL patients [149]. The study was closed at the first interim 
analysis due to the overwhelming advantage of the combination therapy over rituximab and 
this led to the approval of idelalisib in combination with rituximab by the FDA and the 
EMA in 2014. Idelalisib proved to be effective in patients harboring TP53 disruptions; an 
extension study of all patients treated with idelalisib and rituximab in combination yielded 
a median PFS of 19 months in patients with TP53 disruption and 21 months in patients 
without TP53 disruption [24]. 
Further, in a phase 2 study of idelalisib in previously untreated CLL, serious 
autoimmune-mediated adverse events, such as transaminitis, hepatitis, pneumonitis and 
colitis were reported [150]. One hypothesis is that immune-mediated idelalisib-related 
toxicities are caused by inhibition of Treg. Treg express PI3Kδ and inhibition of this enzyme 
leads to suppression of Treg and thus activation of CD4+ and CD8+ effector lymphocytes. 
This hypothesis has been supported by clinical evidence since CD8+ T-cell infiltrates were 
seen in tissue biopsies of patients who experienced colitis or hepatitis [150, 151]. The 
activation of effector lymphocytes appears more pronounced in younger or treatment-naive 
patients or those treated concomitantly with another immunomodulating agent. These 
autoimmune toxicities generally respond to steroids [150]. 
Despite the reported autoimmune adverse events, three phase 3 trials (NCT01732913, 
NCT01732926, NCT01980888) investigating idelalisib in combination with rituximab vs 
chemotherapy in treatment-naive or early line patients were launched. In 2016, these 3 
trials were prematurely stopped due to increased deaths and serious adverse events in 
patients receiving idelalisib. In particular, increased rates of opportunistic infections: fatal 
CMV infections and PJP were reported [152]. Therefore, prophylaxis for PJP and monitoring 
for CMV reactivation are now recommended during idelalisib therapy [152]. This 
demonstrates that idelalisib causes other immunomodulatory effects, besides autoimmune 
toxicity.  
Idelalisib in combination with rituximab is now approved for patients who have 
received at least one prior therapy, or as first-line treatment in patients with TP53 
disruption who cannot be treated with any other therapy.  
2.7.2 Duvelisib 
Duvelisib is an oral inhibitor of PI3Kδ (Figure 1) and, in contrast to idelalisib, also a strong 
inhibitor of PI3Kγ. The value of inhibiting PI3Kγ in CLL is unknown. Duvelisib has 
proven to be effective in relapsed/refractory CLL patients. A phase 3 randomized clinical 
trial (DUO) included patients with relapsed/refractory CLL that were randomized to either 
duvelisib or ofatumumab [153]. The ORR was higher for the duvelisib group compared to 
the ofatumumab group (74% vs 45%), with nearly all responses being PR. The median PFS 
was 13 months in the duvelisib arm vs 10 months in the ofatumumab arm. Adverse events 
grade 3 occurred in 87% in the duvelisib arm compared to 48% in the ofatumumab arm. 
Adverse events during duvelisib treatment included neutropenia, infections, diarrhea, and 
colitis, which occurred as frequently as during idelalisib treatment [154]. Pneumonitis and 
transaminitis seemed less frequent with duvelisib. Based on this study, the FDA approved 
duvelisib for relapsed/refractory CLL patients having had at least 2 lines of prior therapy.   
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2.8 B cell lymphoma 2 (BCL2) inhibitor: venetoclax 
In CLL, the prosurvival intracellular protein BCL2 is highly expressed, which is one of the 
main mechanisms of pathogenesis. Apoptosis is regulated by a complex interplay of pro-
apoptotic and pro-survival proteins triggered by intracellular and extracellular signals. The 
most important effectors of apoptosis are the proteins BCL2 associated X (BAX) and 
BCL2 agonist/killer 1 (BAK). Both proteins permeabilize the outer membrane of the 
mitochondrion leading to a release of cytochrome C into the cytoplasm with a resulting 
activation of caspases and apoptosis [155]. This action is initiated by the proapoptotic BCL2 
homology 3 (BH3) -only family of proteins. Under normal cellular circumstances the BH3-
only family proteins are bound to pro-survival protein, such as BCL2, myeloid cell 
leukemia 1 (MCL1) and B-cell lymphoma-extra large (BCL-XL), preventing them from 
binding to BAX and BAK [156]. Venetoclax is an oral selective inhibitor of BCL2. 
Venetoclax binds to the BH3-binding pocket on BCL2 thereby displacing pro-apoptotic 
proteins resulting in the activation of BAX and BAK and finally apoptosis (Figure 1).  
In the pivotal phase 2 study in relapsed/refractory patients with TP53 disruption, 
venetoclax induced response in 77% of patients including 20% CR. The 24-month PFS rate 
was 54% [157]. In patients failing ibrutinib therapy, venetoclax showed a response rate of 
65% and a median PFS of 25 months [158]. 
Venetoclax is generally well tolerated. The most important adverse event reported in a 
phase 1 trial was tumor lysis syndrome (TLS), which in one case was fatal [3]. To minimize 
the risk of TLS a ramp-up-schedule was introduced. Hematologic toxicity was neutropenia 
occurring in 31-51% of patients (grade 3-4) and thrombocytopenia occurring in 15-29% 
(grade 3-4). Common non-hematologic adverse events included diarrhea, upper respiratory 
tract infection and cough. 
Acquired resistance to venetoclax is an increasing concern. The most common 
mechanism of resistance is a G101V mutation in the BCL2 binding site for venetoclax and 
the mutation has been detected after 19-42 months of treatment [159, 160]. This mutation 
results in a 180-fold decreased affinity of venetoclax for BCL2 [160]. Due to the concerns of 
acquired resistance with targeted therapies, clinical trials aimed at reaching deep responses 
with time-limited combination therapies. 
2.8.1 Combinations using venetoclax and anti-CD20 antibodies 
Venetoclax-rituximab 
In the randomized phase 3 trial (MURANO), relapsed/refractory CLL patients were treated 
with fixed-duration venetoclax-rituximab or BR. The 3-year PFS rate was significantly 
higher in the venetoclax-rituximab group (71%) than in the BR group (15%). MRD 
negativity was achieved in 62% of patients treated with venetoclax-rituximab and 13% of 
patients treated with BR. MRD negativity at end of treatment predicted for longer PFS. The 
study established a time-limited use of venetoclax and rituximab in relapsed/refractory 
CLL patients [22, 75]. 
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Venetoclax-obinutuzumab 
A phase 3 study including 432 previously untreated patients with coexisting morbidities 
were treated with fixed-duration venetoclax-obinutuzumab or chlorambucil-obinutuzumab. 
Approximately 80% of the patients in the venetoclax-obinutuzumab completed treatment 
and 50% reached CR. The PFS rate at 2 years was significantly higher in the venetoclax-
obinutuzumab group (88% vs 64%) [161]. The study led to the approval of venetoclax in 
combination with obinutuzumab as a first-line treatment by the FDA and EMA. 
In summary, combinations of venetoclax and CD20-antibodies have yielded 
unprecedented CR rates in relapsed/refractory CLL patients. Venetoclax is approved by the 
FDA for all lines of therapy and by the EMA for the treatment of relapsed/refractory 
patients (as monotherapy or in combination with rituximab) and for treatment-naive 
patients (in combination with obinutuzumab). No randomized comparison with a BTK 
inhibitor has been performed.  
2.9 Other immunotherapy 
2.9.1 Immunomodulatory drug: lenalidomide 
Lenalidomide has been explored in clinical trials for CLL treatment. It is an 
immunomodulatory drug with an ORR of 32-47% in patients with relapsed/refractory CLL 
[162-164]. However, CLL patients have shown problems tolerating the lenalidomide 
treatment, with TLS and neutropenia being the best-known toxicities [163]. The mechanisms 
of action for lenalidomide in CLL are not entirely understood, but might include a direct 
tumor cell killing effect, immune modulation and alteration of the tumor microenvironment 
[165]. Lenalidomide has been reported to diminish PD-1 expression of T cells in previously 
treated CLL patients, thus reversing the “exhaustion” of T cells [166]. 
In phase 3 studies, lenalidomide has proven to be efficient as maintenance therapy after 
chemoimmunotherapy [167, 168]. However, with the introduction of BTK inhibitors, the role 
of lenalidomide as maintenance therapy is unclear. Lenalidomide is currently not approved 
for CLL treatment and its possible use in this disease is not established. 
2.9.2 Allogeneic hematopoetic stem cell transplantation 
Until recently, allogeneic HSCT was regarded as the only curative treatment of CLL. 
According to the EBMT, the current indication for allogeneic HSCT requires high-risk 
disease and failure on at least one BCR pathway inhibitor [169]. Allogeneic HSCT should be 
performed when the disease is in remission. Chemoimmunotherapy was used historically, 
but retrospective data support the use of venetoclax or idelalisib in combination with 
rituximab for induction and bridging to allogeneic HSCT [170, 171]. Estimated PFS at 10 
years after allogeneic HSCT was 28% and OS was 35%. Non-relapse mortality was 
40% [172].  
2.10 Selecting the right treatment 
Treatment of CLL patients is becoming more individualized, since there is no single, first-
line or salvage regimen that is widely agreed upon. For treatment-naive patients, ibrutinib 
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has turned out to be superior to other drugs and drug combinations in all subgroups, except 
for fit patients younger than 65 years with mutated IGHV and without TP53 aberration. For 
this group of patients FCR could give a very long remission and possibly even cure [93]. 
However, no drug has proven to be significantly better than any other drug for this group 
and there is still no agreement on how to best treat these patients. The choice of treatment 
depends on age, performance status, comorbidities and del(17p)/TP53 mutation status. 
The U.S. National Comprehensive Cancer Network (NCCN) treatment guidelines 
recommend ibrutinib as first-line treatment of all patients with CLL without del(17p)/TP53 
mutation. For patients with del(17p)/TP53 mutation, participation in a clinical trial should 
be considered. For patients not participating in clinical trials, ibrutinib is recommended [173]. 
Ibrutinib is not subsidized by the Swedish national health care system for first-line 
treatment and national guidelines recommend clinical studies to be considered for all CLL 
patients. For patients not participating in clinical trials, chemoimmunotherapy (FCR, BR or 
chlorambucil-rituximab) is recommended for patients without del(17p)/TP53 mutation and 
ibrutinib for patients with del(17p)/TP53 mutation [58]. If ibrutinib is considered 
inappropriate, venetoclax or idelalisib in combination with rituximab could be used. 
For relapsed patients, no treatment strategy is widely agreed upon. The Swedish 
national guidelines recommend clinical studies for these patients [58]. NCCN recommends 
ibrutinib or venetoclax-rituximab [173]. 
2.11 Emerging therapies 
2.11.1 Reversible BTK inhibitors: vecabrutinib, ARQ-531 and LOXO-305 
Reversible BTK inhibitors bind non-covalently and do not rely upon interaction with the 
cysteine residue (C481). They might be an alternative treatment for patients with ibrutinib 
resistance. Recent data from a phase 1B/2 study on vecabrutinib demonstrated that among 
23 CLL patients who were refractory to a BTK inhibitor, none responded to therapy. The 
next group included in the study will receive a higher treatment dose [174]. Early phase 1 
data on ARQ-531 demonstrated that out of 9 patients with C481S BTK mutation and 
ibrutinib refractoriness, 8 responded to treatment (all PR) [175]. Early phase I data on 
LOXO-305 reported efficacy in CLL, 10 of 13 evaluable patients responded to treatment 
(all PR), including those with BTK or BCL2 mutation [176, 177]. For the reversible BTK 
inhibitors, longer follow-up is needed to evaluate safety and efficacy. 
2.11.2 New CD20-antibody: ublituximab 
Ublituximab is a type I, chimeric, glycoengineered anti‐CD20 recombinant mAb with 
improved ADCC. Ublituximab in combination with umbralisib has shown promising 
results in relapsed/refractory CLL [178], but its role in the spectrum of treatments of CLL 
remains to be further explored. 
2.11.3 New PI3K inhibitor: umbralisib 
Umbralisib is an oral PI3Kδ inhibitor with a different molecular structure than idelalisib 
and duvelisib. The change in molecular structure leads to inhibition of casein kinase 1 
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epsilon (CK1ε) and it may change the toxicity profile. The role of CK1ε in CLL is unclear 
but is has been suggested that inhibition of CK1ε may hinder suppression of Treg mediated 
by PI3Kδ [179]. Thus, umbralisib may have less immune-mediated toxicities than other 
PI3Kδ-inhibitors and might lead to a renaissance for the PI3K inhibitors in CLL. Single 
agent umbralisib proved to be efficient and well tolerated in relapsed/refractory CLL in a 
phase 2 trial for patients who were intolerant to BTK- or PI3Kδ-inhibitors [180]. A phase 3 
study (UNITY-CLL) comparing umbralisib-ublituximab to chlorambucil-obinutuzumab in 
treatment-naive and relapsed/refractory CLL patients is ongoing (NCT02612311).  
2.11.4 Combination of ibrutinib and chemoimmunotherapy 
In the phase 3 HELIOS study, 578 previously treated patients without 17p deletion were 
treated with either ibrutinib or placebo in combination with BR. At a median follow-up of 
35 months, the median PFS was not reached for the ibrutinib-BR arm while it was 14 
months for the placebo-BR arm. Concerning OS, the hazard ratio (HR) was 0.65 for 
ibrutinib vs placebo. Thus, the study reported improved survival with ibrutinib-BR 
compared to BR in relapsed CLL [181]. However, the advantage of adding ibrutinib to 
chemoimmunotherapy has been debated since, in the ibrutinib-BR group the PFS at 36 
months was 68%, being very close to the PFS at 30 months of 69% reported with ibrutinib 
as monotherapy [108]. 
2.11.5 Combinations of BCR inhibitors and BCL2 inhibitors 
Preclinical studies demonstrated a synergistic effect of venetoclax and ibrutinib in 
combination [182]. The safety of this drug combination was first demonstrated in a phase 2 
trial of high-risk CLL patients. Ibrutinib was given as monotherapy for 3 months and then 
in combination with venetoclax for 24 months. If MRD negativity was achieved, treatment 
was discontinued. This study reported 88% CR and 61% CR with MRD negativity [183, 184], 
which was higher than for each agent as monotherapy. The safety profile of venetoclax and 
ibrutinib in combination was similar to known toxicity for both agents separately. Another 
phase 2 study (CAPTIVATE), with a similar design, confirmed these findings [185, 186]. The 
combination has also shown promising results in relapsed/refractory CLL patients. In the 
VISION study, MRD negativity was achieved in 55% of patients and in the CLARITY 
trial, 36% of patients attained MRD negativity [187, 188]. 
In summary, venetoclax and ibrutinib in combination yielded a high frequency of CR 
and MRD negativity and the treatment was well tolerated. However, the follow-up times of 
these studies are still short. Two phase 3 studies with the combination of ibrutinib, 
venetoclax and obinutuzumab aiming at deeper responses are ongoing [189, 190]. 
2.11.6 Checkpoint inhibition: pembrolizumab 
Immune checkpoint inhibition targeting PD-1 has been explored in CLL. In a phase 2 trial 
of a PD-1-blocking antibody, pembrolizumab, responses were reported in 0 out of 16 
refractory CLL patients and in 4 out of 9 patients with RT [191]. Pembrolizumab is now 
explored in combination therapy in CLL and RT [192].  
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2.11.7  Chimeric antigen receptor (CAR) T-cell therapy 
T cells bearing a chimeric antigen receptor (CAR) are produced by genetic engineering and 
they are designed to direct the patient’s T cells against the tumor cells. At present, the most 
advanced CAR T-cells are directed against CD19. A review summarized the results of trials 
on CAR T in 134 heavily pretreated CLL patients between the years 2011 and 2018. CR 
was obtained in 20-30% of patients and at 18 months, PFS was 25%. The effect of CAR T-
cell therapy on RT was partial and transient [193]. The most frequent complications to CAR 
T-cell therapy are cytokine release syndrome and neurological toxicities [194]. Fewer tumor 
cells at the time of injection lead to less cytokine release and thus to less toxicities [194].  
Recent data on the CD19-targeted CAR T-cell therapy, lisocabtagene-maraleucel (liso-
cel), which is given in a predefined composition of CD4+ and CD8+ T lymphocytes, were 
promising. In 23 relapsed/refractory CLL patients, 82% responded to treatment. Most 
patients had deepening responses with time. However, the follow-up time was only 11 
months [195]. 
Efficacy of CAR T seems lower in CLL than in acute lymphoblastic leukemia and 
DLBCL. This could in part be due to the T cell exhaustion seen in CLL [196]. Data suggest 





The aims of this thesis are to explore safety and efficacy of targeted agents in patients with 
advanced-phase chronic lymphocytic leukemia. 
 
More specifically: 
I. To obtain knowledge about the safety and efficacy of lenalidomide and 
alemtuzumab in combination therapy and to examine whether low-dose 
lenalidomide could stimulate and maintain immune functions in very advanced-
phase CLL during therapy with alemtuzumab. 
 
II. To obtain knowledge of the safety and efficacy of ibrutinib and alemtuzumab in 
combination therapy in previously treated CLL patients. 
 
III. To obtain knowledge about the efficacy and safety of ibrutinib in consecutive 
patients with advanced-phase CLL when used in routine health care.  
 
IV. To obtain knowledge about the long-term efficacy and safety of ibrutinib in 
consecutive patients with advanced-phase CLL when used in routine health 
care.  
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4 MATERIAL AND METHODS 
4.1 Evaluation of response and toxicity 
Treatment response was classified according to the IWCLL response criteria of 2008 with 
the exception that lymphocytosis was not the sole criterion for disease progression [73, 198]. 
Response evaluation in patients with SLL was based on the 2007 International Working 
Group Criteria for non-Hodgkin lymphoma [199]. CR required evaluation by computed 
tomography scan and bone marrow examination. Cumulative Illness Rating Scale (CIRS) 
was used to define comorbidities at baseline [200]. 
Treatment toxicity was evaluated using the National Cancer Institute (NCI) Common 
Terminology Criteria for Adverse Events v3.0 except for anemia, thrombocytopenia and 
neutropenia, which were graded according to the IWCLL grading scale for hematologic 
toxicity in studies [198]. In Paper I and II, adverse events of all grades were recorded. In 
Paper III, adverse events of grade 3 or higher were recorded, whereas any grade of adverse 
events was reported for hemorrhage, diarrhea, arthralgia, atrial fibrillation and blood 
counts. In Paper IV, adverse events of grade 3 or higher were recorded, with the exception 
of atrial fibrillation for which all grades were recorded.  
4.2 Study procedures 
4.2.1 Paper I and II 
Consecutive patients with chemotherapy-refractory CLL were included in the studies. 
Adequate organ function and Eastern Cooperative Oncology Group (ECOG) performance 
status ≤ 2 were required. All patients had bacterial and viral prophylaxis and, if needed, G-
CSF.  
4.2.2 Paper III and IV 
All patients in the compassionate use program for ibrutinib in Sweden were identified and 
included in this retrospective real-world study. The compassionate use program was open 
for inclusion between May 15, 2014 and May 31, 2015 and all the included patients were 
identified. Patients from 27 hospitals were included. Data were extracted from the medical 
files of the patients and entered into case record forms (CRF) by each treating physician. 
The data from individual patient files were crosschecked by the academic study team.  
Patients were eligible for the compassionate use program if they had chemotherapy-
refractory CLL or del(17p)/TP53 aberration, adequate organ function and ECOG 
performance status ≤ 2 and had not undergone an allogeneic HSCT within the last 6 
months. Baseline comorbidities were evaluated by CIRS score. 
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4.3 Laboratory methods 
4.3.1 Paper I 
Immune monitoring was performed at baseline, at week 4, 16, 30 and 45. Laboratory 
methods are described in detail in paper I. 
 
Flow cytometric analysis of whole blood lymphocytes 
After lysis of red blood cells, cells were washed and stained according to the 
manufacturer’s recommendation using fluorochrome-coupled antibodies. Flow cytometric 
analysis was done for CD19, CD3, CD4, CD8, CD16, CD56, CD52, CD45RA, human 
leukocyte antigen-antigen D related (HLA-DR) and C-C motif chemokine receptor 
(CCR)7. 
 
Flow cytometric analysis of peripheral blood mononuclear cells (PBMC) 
Peripheral blood mononuclear cells (PBMC) were isolated from fresh blood by using Ficoll 
gradient density separation. Cells were freshly used or stored in liquid nitrogen until use. 
The PBMC for flow cytometry were mixed with appropriate amount of fluorochrome-
coupled antibodies for PD-1, PD-L1, CCR6, CXCR3, CD25 and HLA-DR. 
For intracellular staining, cells were resuspended in fixation/permeabilization buffer, 
incubated for 30 min at 4 °C and washed with permeabilization buffer. Antibodies (FOXp3, 
granzyme B, perforin and Ki67) were added to the resuspended cells and incubated for 30 
min at room temperature. Excess of antibodies was removed by washing twice with 
permeabilization buffer. The cells were then resuspended in cell staining buffer (CSB) and 
analyzed by flow cytometry. 
4.3.2 Paper II 
Immune monitoring was performed at baseline, at week 2, 4, 10, 16, 21 and 32. Laboratory 
methods have previously been described in detail [61]. 
 
Flow cytometric analysis of whole blood lymphocytes 
After lysis of red blood cell, cells were washed and stained for CD19, CD16, CD56, 
CD4, CD3, CD8 and CD45. After incubation and washing, cells were resuspended in 
CSB and analyzed by flow cytometry. 
 
Flow cytometric analysis of PBMC 
PBMC were isolated from fresh blood by using Ficoll density gradient separation. Cells 
were freshly used or stored in liquid nitrogen until use. Flow cytometric analysis of PBMC 
was done for CD19, CD4, CD5, CD3, CD8, CD45RA, PD-1, CD69, Ki67, HLA-DR, 
CD52, CCR6, CCR4, CD127, CXCR3, CCR7, PD-L1, Ror1 and CD20 and the 
appropriate isotype controls. 
To assess Ki67 expression, freshly isolated PBMC cells were fixed with 1.6% 
paraformaldehyde and permeabilized with 80% methanol. The cells were then stained 
with both the appropriate surface antibodies and the anti-Ki67 or isotype control. 
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4.3.3 Paper IV 
The testing for BTK mutation in 4 of the 6 patients who had PD while on ibrutinib 
treatment was done with Sanger sequencing. 
4.4 Statistical analysis 
4.4.1 Paper I and II 
Survival analysis was done with the Kaplan-Meier method. Comparison of marker 
expression at different time points was done with the Wilcoxon signed-rank test for related 
samples. All tests were two-sided and p < 0.05 was considered significant.  
4.4.2 Paper III and IV 
Time to response was defined as the time from start of ibrutinib until the date of fulfilling 
criteria for PR-L, PR or CR. PFS was defined as the time from start of treatment until PD, 
the start of new anti-cancer treatment or death from any cause. Patients, who proceeded to 
allogeneic HSCT or had donor lymphocyte infusion after having responded to treatment, 
were excluded from PFS analysis. OS was defined as the time from start of ibrutinib 
treatment to death or latest follow-up. 
Response rates were presented with 95% confidence intervals (CI). Survival (PFS, OS) 
was estimated by the Kaplan-Meier method. Univariate and multivariate analyses of time to 
failure were estimated using the Cox proportional regression hazards model. Results are 
presented as HR with 95% CI.  
In exploratory analyses, characteristics associated with PFS and OS were identified. 
Patients were grouped according to each characteristic and groups were compared by 
means of log-rank test.  
4.5 Ethical aspects 
All studies were approved by the Regional Ethics Committee. Patients who were included 
in the studies in Paper I and II provided informed consent. Since the studies in Paper III and 
IV were retrospective, no informed consent was required. The studies in Paper I and II 
were approved by the Medical Products Agency.  
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5 RESULTS, DISCUSSION AND CONCLUSIONS 
5.1 Paper I 
Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic 
leukemia (CLL): effects on T cells and immune checkpoints 
Winqvist et al. Cancer Immunol Immunother, 66(1):91-102, 2017 
When this study was initiatied, there was no consensus on how to treat refractory/relapsed 
CLL patients. Alemtuzumab was the most frequently used drug in this clinical situation, 
but treatment results of alemtuzumab as monotherapy were dismal and resulting 
opportunistic infections were of great concern. The rational for combining alemtuzumab 
and lenalidomide was based on the assumption that lenalidomide might stimulate immune 
functions, thus preventing the negative effect on T cells seen with alemtuzumab. 
Furthermore, lenalidomide has its major effects in lymph nodes and alemtuzumab in the 
blood and bone marrow. A phase I trial, in which 12 refractory CLL patients were included, 
explored the safety and efficacy of lenalidomide and alemtuzumab in combination [201]. The 
present study was an extension of the phase I study and included 11 additional refractory 
CLL patients.  
In total, 23 consecutive patients were enrolled. They were treated with lenalidomide 
alone during the first 4 weeks and alemtuzumab was added at week 5. Maxiumum 
treatment period was 16 weeks of lenalidomide and 12 weeks of alemtuzumab.  
The combination showed an acceptable safety profile and clinical activity with 58% 
ORR.  Median PFS was 6 months and median OS was 17 months. The median response 
duration was 12 months (range 1-29). Lenalidomide had a narrow therapeutic dose range; 
2.5 mg/day was not efficient and the maximal tolerated dose was 5 mg/day.  The most 
common grade 3-4 adverse event was neutropenia (84% of patients), which was also the 
dose limiting toxicity. Febrile neutropenia occurred in 30% of patients and CMV 
reactivation requiring valganciclovir occured in 30%. Grade 3-4 thrombocytopenia 
occurred in 55%.  
Immune stimulation was apparent after 4 weeks of low-dose lenalidomide. It was 
indicated by an increased frequency of proliferating (Ki67+) CD8+ T cells accompanied by 
an increased frequency of activated (HLA-DR+) T cells. Furthermore, the frequency of 
antigen-experienced CD8+ effector memory cells increased at week 4, while effector cells 
decreased in both the CD4+ and CD8+ subsets.  
After combination treatment all the lymphoid subsets decreased dramatically. T cells 
shifted towards a type 2 T helper cell (Th2) profile. The frequencies of type 17 T helper 
cells (Th17) and Treg were reduced. The proportion of granzyme B+ T cells increased at 30-
week follow-up, indicating an enhanced cytotoxic potential. PD-1 expression was 
unaffected at all analyzed points of time.  
In conclusion, lenalidomide and alemtuzumab is an active combination in refractory 
CLL, but with novel targeted therapies the treatment combination is of very limited use. 
Further, low-dose lenalidomide and alemtuzumab had major effects on T cells including 
increased proliferative activity and cytotoxic potential. 
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5.2 Paper II 
Dual targeting of Bruton tyrosine kinase and CD52 induces minimal residual disease-
negativity in the bone marrow of poor-prognosis chronic lymphocytic leukemia 
patients but is associated with opportunistic infections - Results from a phase I study 
Winqvist et al. Br J Haematol, 182(4):590-4, 2018 
The safety and efficacy of ibrutinib in the combination with alemtuzumab was explored in 
this phase I study. The rationale for the combination was that ibrutinib has its major effects 
in lymph nodes while alemtuzumab has effects in the blood and bone marrow. Moreover, 
the drugs have different mechanisms of action and different toxicity profiles. Eight patients 
with advanced-phase CLL were included. They were treated with ibrutinib alone during the 
first 4 weeks and alemtuzumab was added at week 5.  
Seven patients responded to treatment (4 had CR and 3 had PR). All but one reached 
MRD negativity in the bone marrow. One patient developed progressive multifocal 
leucoencephalopathy (PML) and two patients developed Aspergillus pneumonia.  
During the monotherapy with ibrutinib the percentage of proliferating (Ki67+) T cells 
decreased and the proportion of proliferating (Ki67+) CLL cells became undetectable.  The 
balance of type 1 T helper cells (Th1) and Th2 was unaffected, as well as the PD-1-
expression on T cells. Other studies have reported a decrease in PD-1 expression [128, 129]. 
The divergent results could be explained by the limited time of ibrutinib monotherapy in 
our study. Moreover, the expression of CD20 and CD52 on CLL cells decreased. 
After combination therapy, the frequencies of Th17 cells and Treg were significantly 
reduced. Further, there was a shift to a Th2 profile. These findings confirmed the findings 
of Study I. PD-1 expression on T cells increased with combination therapy. This finding 
was contrary to the findings in Study I. Therefore, control experiments were done to 
determine the effects of the single agent alemtuzumab. These experiments indicated that 
the increase of PD-1 on T cells was attributable to alemtuzumab. Immune profiling was 
consistent with immunosuppression, as defined by increase of PD-1 expressing T cells and 
the Th2 shift. 
The study was closed in advance due to the high rate of opportunistic infections. We 
advise against the combination of ibrutinib and alemtuzumab.  
5.3 Paper III 
Real-world results of ibrutinib in patients with relapsed or refractory chronic 
lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate 
use program. A study from the Swedish Chronic Lymphocytic Leukemia Group. 
Winqvist et al. Haematologica, 101(12):1573-80, 2016 
Randomized controlled trials (RCT) are the standard prerequisite for treatment guidelines. 
Discrepancies of results between clinical trials and routine health care are commonly 
observed in oncology/hematology, as shown in CLL patients with the FCR regimen [1, 202]. 
Clinical trials are conducted in selected populations that differ from patients in routine 
health care. Clinical trials in CLL more frequently enroll younger patients with less 
comorbidity than patients in routine health care. Further, clinical trials use extensive 
monitoring and specialized research staff to ensure adherence to a standard protocol. 
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Hence, the internal validity of clinical trials is high, but often at a cost of less 
generalizability (external validity). Thus, real-world studies may provide important data on 
treatments in a wider population, reflecting patients in routine health care. Real-world 
studies may also generate data on concomitant comorbidities and medications. Further, 
real-world studies are generally more cost-effective and rapid than RCTs. However, real-
world studies generally are affected by lower internal validity and susceptibility to selection 
bias.  
Several new, targeted agents in oncology/hematology are subject to the FDA 
accelerated approval program, which allows a faster approval of drugs targeting serious 
illnesses with an unmet clinical need. Real-world evidence can play a role to support 
accelerated approval and the FDA has expressed their interest in more frequent use of real-
world evidence [132]. 
In Paper III, 95 consecutive patients in a compassionate use program for ibrutinib were 
identified and included in the retrospective study. The median age was 69 years. Sixty-
three percent had TP53 aberration. At a median follow-up of 10.2 months the ORR was 
84%, the PFS rate was 77% and the OS rate was 83%. PFS and OS were significantly 
shorter for patients with del(17p)/TP53 aberration, no other factor turned out to be 
significant in the Cox proportional regression model.  
Twenty-four percent of patients discontinued ibrutinib due to PD (n=10), adverse 
events (n=10) or due to other reasons (n=3). Ibrutinib was well tolerated. The most 
common non-hematologic grade 3-4 adverse event was infection. Hematomas occurred in 
46% of patients, all of them grade 1-2. Eight percent had atrial fibrillation. Seven patients 
showed RT occurring after a median time of 9.5 months. 
Half of the patients would not have fulfilled the inclusion criteria for the pivotal 
ibrutinib trial (RESONATE). This fact demonstrates the real-world attributes of the 
patients. The results from this study show that efficacy and toxicity of ibrutinib in routine 
health care was similar to that of pivotal trials. 
5.4 Paper IV 
Long-term real-world results of ibrutinib therapy in patients with relapsed or 
refractory chronic lymphocytic leukemia: 30-month follow-up of the Swedish 
compassionate use cohort. 
Winqvist et al. Haematologica, 104(5):E208-E10, 2019 
Paper IV is a long-term follow-up of the 95 patients in the compassionate use program for 
ibrutinib. At 30-month follow-up, the ORR was unchanged compared to the 10-month 
follow-up. The CR rate was not evaluable since bone marrow examinations were only 
carried out in a few patients. The PFS rate was 52% and the OS rate was 63%. In contrast 
to the early (10-month) report there was no negative survival impact of TP53 aberration. In 
multivariate analyses, PFS was significantly associated with baseline comorbidities and 
number of prior therapies, while OS only with baseline comorbidities. As mentioned above, 
44% of the patients in the study did not meet the inclusion criteria for the pivotal ibrutinib 
trial, RESONATE. The most frequent criterion that would have excluded the patients in 
was ECOG performance status ≥ 2. OS was significantly shorter for patients who did not 
match the RESONATE inclusion criteria.  
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The observed PFS and OS in our study were shorter than in the pivotal phase 3 study, 
RESONATE. The explanation for the inferior PFS and OS in our study when compared to 
the pivotal study, RESONATE, could in part be attributed to a larger percentage of patients 
with TP53 aberration (27% in RESONATE vs 63% in our study), since these patients seem 
to have a shorter survival on ibrutinib. Moreover, “real-world-factors” such as comorbidity 
and performance status probably partially explain the difference. 
Fifty-one percent of the patients had grade 3-4 infections and 13% had grade 3-5 
opportunistic infections. Fifteen percent developed atrial fibrillation at 30-month follow-up. 
This is, in comparison with the cumulative incidence of atrial fibrillation of 8% at 10-
month follow-up, implying that the risk of atrial fibrillation is substantial during long-term 
treatment. RT occurred in 13 % after a median time of 14 months.  
In our study, 49% discontinued treatment. The reasons for treatment discontinuation 
were toxicity (n=19), RT (n=11), CLL progression (n=6), allogeneic HSCT (n=4), second 
malignancy (n=3), need of dual platelet therapy (n=3) and sudden death (n=1). Thus, 20% 
of patients discontinued due to toxicity. The most common toxicity leading to treatment 
interruption was infection. In a 3-year follow-up of the phase 2 study PCYC-1102/1103, 
28% of patients interrupted treatment and 11% discontinued due to toxicity [108]. Thus, 
discontinuation of treatment, and particularly due to toxicity was more frequent in our 
study. Other real-world studies also reported higher rate of discontinuations in comparison 
to clinical studies [133, 134, 136]. 
Twenty-six percent of patients experienced dose reductions or temporary treatment 
breaks. Survival (PFS and OS) was not inferior for these patients. The observed frequency 
of dose reductions in our study was greater than in clinical trials [108].  
Four of six patients who had PD while on ibrutinib were tested for mutation of BTK 
and all of them carried the C481S mutation, which is in line with the abovementioned 
findings from a French real-world study [131].  
In conclusion, ibrutinib is effective and well tolerated for long-term treatment in 
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6 FUTURE PERSPECTIVES 
During recent years, a remarkable change in treatment of CLL has occurred. There is a shift 
towards targeted therapies in routine health care and in a near future chemoimmunotherapy 
might not be an alternative among the standard treatments of CLL. In the era of targeted 
treatment, many questions concerning clinical applications remain unanswered.  
The “watch and wait” strategy might be challenged by new therapies. Especially, for 
high-risk patients, start of therapy at an earlier stage of disease might be considered [190, 203].  
Ibrutinib has shown unprecedented results, especially in high-risk patients. However, 
this therapy raises concerns about residual disease, acquired resistance and continuous 
treatment. Our work and the work by others show that non-tolerability and discontinuation 
are recurrent events during ibrutinib treatment [121, 133, 134]. It is uncertain if the treatment can 
be discontinued safely and if so, at what depth of remission or length of therapy. At present, 
our group is carrying out an academic study to search for an answer. Further, second-
generation BTK inhibitors, such as acalabrutinib and zanubrutinib, might limit off-target 
toxicity and reversible (non-covalent) BTK inhibitors such as vecabrutinib and LOXO-305 
may overcome the problems of acquired resistance due to BTK point mutation. However, 
BTK inhibitors rarely lead to CR or MRD negativity.  
Venetoclax in combination with CD20-mAbs have resulted in deep remissions and a 
high rate of MRD negativity [161]. The relative efficacy of ibrutinib vs venetoclax in 
combination with a CD20-mAb in the first-line setting is still unknown and a phase 3 study 
(CLL17) will seek the answer to this question. The results might give insight in the optimal 
sequencing of targeted therapies.  
It was demonstrated that MRD negativity translated into longer remissions [75]. 
Therefore, studies are now aiming at even deeper remission with the aim of achieving long 
treatment-free intervals or even cure. A time limited therapy with a triple-combination 
including a BCR inhibitor, a BCL2 inhibitor and a CD20-mAb seemed to yield 
unprecedented MRD negativity rates [204]. Besides, the combination showed good 
tolerability. Such triple-combinations are likely to be the future approach in CLL therapy. 
However, more clinical data is needed before it could be given in routine practice. Two 
phase 3 studies (NCT03701282, NCT03737981) investigate the effect of venetoclax as a 
supplement to obinutuzumab-ibrutinib in the first-line setting. 
 






I would like to thank all those who have contributed to the completion of this thesis.  
In particular, I wish to thank:  
First and foremost, the participating patients. 
Jeanette Lundin, my main supervisor, for introducing me to the field of CLL and her 
guidance through each stage of the process with patience, commitment and encouragement.  
Anders Österborg, my co-supervisor, for your broad scientific knowledge, wise inputs and 
support.  
Marzia Palma, my co-supervisor, for teaching everything about laboratory methods, and 
for enthusiasm and for supportive comments. 
Lotta Hansson, my co-supervisor, for being supportive of my work and for giving good 
advice. 
Kia Heimersson and Fariba Mozaffari for teaching me so much about laboratory work. 
Leila Relander for being so helpful and skillful at editing manuscripts. 
All the other members of the Österborg-Mellstedt group. 
All the co-authors of the papers. 
All superiors who over the years have given me time for research. 
All colleagues and friends at the Hematology Department. I am looking forward to our 
further collaboration at the clinic. 
Finally, I would like to express my deepest gratitude to my family and friends. This thesis 
would not have been possible without your warm love and support. In particular, I am 





1. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and 
cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, 
phase 3 trial. Lancet. 2010; 376(9747): 1164-74 
2. Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic 
lymphoid leukemia. N Engl J Med. 2014; 371(3): 213-23 
3. Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with Venetoclax in Relapsed 
Chronic Lymphocytic Leukemia. N Engl J Med. 2016; 374(4): 311-22 
4. Shenoy PJ, Malik N, Sinha R, et al. Racial Differences in the Presentation and Outcomes of 
Chronic Lymphocytic Leukemia and Variants in the United States. Clinical Lymphoma 
Myeloma & Leukemia. 2011; 11(6): 498-506 
5. Mattsson M, Sandin F, Kimby E, et al. Increasing prevalence of chronic lymphocytic leukemia 
with an estimated future rise: A nationwide population-based study. Am J Hematol. 2020; 95(2): 
E36-E8 
6. Regionala cancercentrum i samverkan. KLL Årsrapport från nationella kvalitetsregistret 2019. 
www.sfhem.se/rapporter-blodcancerregistret. Cited: March 20, 2020.  
7. Cerhan JR, Slager SL. Familial predisposition and genetic risk factors for lymphoma. Blood. 
2015; 126(20): 2265-73 
8. Slager SL, Benavente Y, Blair A, et al. Medical history, lifestyle, family history, and 
occupational risk factors for chronic lymphocytic leukemia/small lymphocytic lymphoma: the 
InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014; (48): 
41-51 
9. Fabbri G, Dalla-Favera R. The molecular pathogenesis of chronic lymphocytic leukaemia. 
Nature Reviews Cancer. 2016; 16(3): 145-62 
10. Landau DA, Tausch E, Taylor-Weiner AN, et al. Mutations driving CLL and their evolution in 
progression and relapse. Nature. 2015; 526(7574): 525-U132 
11. Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V-H genes are associated with a more 
aggressive form of chronic lymphocytic leukemia. Blood. 1999; 94(6): 1848-54 
12. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel 
prognostic indicators in chronic lymphocytic leukemia. Blood. 1999; 94(6): 1840-7 
13. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic 
lymphocytic leukemia. New England Journal of Medicine. 2000; 343(26): 1910-6 
14. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro- 
RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U 
S A. 2002; 99(24): 15524-9 
15. Zenz T, Mertens D, Kuppers R, et al. From pathogenesis to treatment of chronic lymphocytic 
leukaemia. Nature Reviews Cancer. 2010; 10(1): 37-50 
16. Schaffner C, Stilgenbauer S, Rappold GA, et al. Somatic ATM mutations indicate a pathogenic 
role of ATM in B-cell chronic lymphocytic leukemia. Blood. 1999; 94(2): 748-53 
17. Stilgenbauer S, Schnaiter A, Paschka P, et al. Gene mutations and treatment outcome in chronic 
lymphocytic leukemia: results from the CLL8 trial. Blood. 2014; 123(21): 3247-54 
18. Zenz T, Eichhorst B, Busch R, et al. TP53 mutation and survival in chronic lymphocytic 
leukemia. J Clin Oncol. 2010; 28(29): 4473-9 
19. Zenz T, Mohr J, Edelmann J, et al. Treatment resistance in chronic lymphocytic leukemia: the 
role of the p53 pathway. Leuk Lymphoma. 2009; 50(3): 510-3 
20. Zenz T, Krober A, Scherer K, et al. Monoallelic TP53 inactivation is associated with poor 
prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with 
long-term follow-up. Blood. 2008; 112(8): 3322-9 
21. Seiffert M, Dietrich S, Jethwa A, et al. Exploiting biological diversity and genomic aberrations 
in chronic lymphocytic leukemia. Leukemia & Lymphoma. 2012; 53(6): 1023-31 
22. Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-Rituximab in Relapsed or Refractory 
Chronic Lymphocytic Leukemia. New England Journal of Medicine. 2018; 378(12): 1107-20 
References 33 
 
23. O'Brien S, Furman RR, Coutre S, et al. Single-agent ibrutinib in treatment-naive and 
relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood. 2018; 131(17): 
1910-9 
24. Sharman JP, Coutre SE, Furman RR, et al. Final Results of a Randomized, Phase III Study of 
Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With 
Relapsed Chronic Lymphocytic Leukemia. Journal of Clinical Oncology. 2019; 37(16): 1391-+ 
25. Winqvist M, Asklid A, Andersson PO, et al. Real-world results of ibrutinib in patients with 
relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated 
in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia 
Group. Haematologica. 2016; 101(12): 1573-80 
26. Blakemore SJ, Clifford R, Parker H, et al. Clinical significance of TP53, BIRC3, ATM and 
MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF 
CLL4 trial. Leukemia. 2020: 15 
27. Nadeu F, Delgado J, Royo C, et al. Clinical impact of clonal and subclonal TP53, SF3B1, 
BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. Blood. 2016; 
127(17): 2122-30 
28. Young E, Noerenberg D, Mansouri L, et al. EGR2 mutations define a new clinically aggressive 
subgroup of chronic lymphocytic leukemia. Leukemia. 2017; 31(7): 1547-54 
29. Landau DA, Carter SL, Stojanov P, et al. Evolution and Impact of Subclonal Mutations in 
Chronic Lymphocytic Leukemia. Cell. 2013; 152(4): 714-26 
30. Bozic I, Nowak MA. Timing and heterogeneity of mutations associated with drug resistance in 
metastatic cancers. Proceedings of the National Academy of Sciences of the United States of 
America. 2014; 111(45): 15964-8 
31. Zenz T, Habe S, Denzel T, et al. Detailed analysis of p53 pathway defects in fludarabine-
refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, 
TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood. 2009; 
114(13): 2589-97 
32. Rossi D, Khiabanian H, Spina V, et al. Clinical impact of small TP53 mutated subclones in 
chronic lymphocytic leukemia. Blood. 2014; 123(14): 2139-47 
33. Lagneaux L, Delforge A, Bron D, et al. Chronic lymphocytic leukemic B cells but not normal B 
cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood. 
1998; 91(7): 2387-96 
34. Burger JA, Gribben JG. The microenvironment in chronic lymphocytic leukemia (CLL) and 
other B cell malignancies: Insight into disease biology and new targeted therapies. Seminars in 
Cancer Biology. 2014; 24: 71-81 
35. Burger JA, Tsukada N, Burger M, et al. Blood-derived nurse-like cells protect chronic 
lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. 
Blood. 2000; 96(8): 2655-63 
36. Filip AA, Cisel B, Wasik-Szczepanek E. Guilty bystanders: nurse-like cells as a model of 
microenvironmental support for leukemic lymphocytes. Clinical and Experimental Medicine. 
2015; 15(1): 73-83 
37. Burger JA, Quiroga MP, Hartmann E, et al. High-level expression of the T-cell chemokines 
CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after 
BCR stimulation. Blood. 2009; 113(13): 3050-8 
38. Ruan J, Hyjek E, Kerman P, et al. Magnitude of stromal hemangiogenesis correlates with 
histologic subtype of non-Hodgkin's lymphoma. Clinical Cancer Research. 2006; 12(19): 5622-
31 
39. Man S, Henley P. Chronic lymphocytic leukaemia: the role of T cells in a B cell disease. British 
Journal of Haematology. 2019; 186(2): 220-33 
40. Jitschin R, Braun M, Buttner M, et al. CLL-cells induce IDOhi CD14(+)HLA-DRlo myeloid-
derived suppressor cells that inhibit T-cell responses and promote T-Regs. Blood. 2014; 124(5): 
750-60 
41. Ferrer G, Montserrat E. Critical molecular pathways in CLL therapy. Molecular Medicine. 
2018; 24: 10 
42. Duhren-von Minden M, Ubelhart R, Schneider D, et al. Chronic lymphocytic leukaemia is 
driven by antigen-independent cell-autonomous signalling. Nature. 2012; 489(7415): 309-+ 
34 References 
 
43. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization 
classification of lymphoid neoplasms. Blood. 2016; 127(20): 2375-90 
44. Shanafelt TD, Ghia P, Lanasa MC, et al. Monoclonal B-cell lymphocytosis (MBL): biology, 
natural history and clinical management. Leukemia. 2010; 24(3): 512-20 
45. Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. 
Blood. 1975; 46(2): 219-34 
46. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic 
leukemia derived from a multivariate survival analysis. Cancer. 1981; 48(1): 198-206 
47. Hallek M, Group TC-IW. An international prognostic index for patients with chronic 
lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncology. 
2016; 17(6): 779-90 
48. Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for 
treatment, response assessment, and supportive management of CLL. Blood. 2018; 131(25): 
2745-60 
49. Durani U, Go RS, Kay NE. Immune-Mediated Hemolytic Anemia and Thrombocytopenia in 
Clonal B-Cell Disorders: A Review. Clinical Advances in Hematology & Oncology. 2018; 
16(10): 670-6 
50. Visco C, Novella E, Peotta E, et al. Autoimmune hemolytic anemia in patients with chronic 
lymphocytic leukemia is associated with IgVH status. Haematologica-the Hematology Journal. 
2010; 95(7): 1230-2 
51. Zent CS, Ding W, Schwager SM, et al. The prognostic significance of cytopenia in chronic 
lymphocytic leukaemia/small lymphocytic lymphoma. British Journal of Haematology. 2008; 
141(5): 615-21 
52. Borthakur G, O'Brien S, Wierda WG, et al. Immune anaemias in patients with chronic 
lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab - incidence 
and predictors. British Journal of Haematology. 2007; 136(6): 800-5 
53. De Back TR, Kater AP, Tonino SH. Autoimmune cytopenias in chronic lymphocytic leukemia: 
a concise review and treatment recommendations. Expert Review of Hematology. 2018; 11(8): 
613-24 
54. Teh BW, Tam CS, Handunnetti S, et al. Infections in patients with chronic lymphocytic 
leukaemia: Mitigating risk in the era of targeted therapies. Blood Rev. 2018; 32(6): 499-507 
55. Arruga F, Gyau BB, Iannello A, et al. Immune Response Dysfunction in Chronic Lymphocytic 
Leukemia: Dissecting Molecular Mechanisms and Microenvironmental Conditions. Int J Mol 
Sci. 2020; 21(5): 1825 
56. Patel SY, Carbone J, Jolles S. The Expanding Field of Secondary Antibody Deficiency: Causes, 
Diagnosis, and Management. Frontiers in Immunology. 2019; 10: 22 
57. Friman V, Winqvist O, Blimark C, et al. Secondary immunodeficiency in lymphoproliferative 
malignancies. Hematological Oncology. 2016; 34(3): 121-32 
58. Regionala cancercentrum i samverkan. Kronisk lymfatisk leukemi (KLL), Nationellt 
vårdprogram 2019. http://www.sfhem.se/Files.aspx?f_id=161523. Cited: March 13, 2020.  
59. Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu 
Rev Immunol. 2008; 26: 677-704 
60. Riches JC, Davies JK, McClanahan F, et al. T cells from CLL patients exhibit features of T-cell 
exhaustion but retain capacity for cytokine production. Blood. 2013; 121(9): 1612-21 
61. Palma M, Gentilcore G, Heimersson K, et al. T cells in chronic lymphocytic leukemia display 
dysregulated expression of immune checkpoints and activation markers. Haematologica. 2017; 
102(3): 562-72 
62. Brusa D, Serra S, Coscia M, et al. The PD-1/PD-L1 axis contributes to T-cell dysfunction in 
chronic lymphocytic leukemia. Haematologica. 2013; 98(6): 953-63 
63. Kay NE, Zarling JM. Impaired natural-killer activity in patients with chronic lymphocytic 
leukemia is associated with a deficiency of azurophilic cytoplasmic granules in putative NK 
cells. Blood. 1984; 63(2): 305-9 
64. Palmer S, Hanson CA, Zent CS, et al. Prognostic importance of T and NK-cells in a consecutive 
series of newly diagnosed patients with chronic lymphocytic leukaemia. British Journal of 
Haematology. 2008; 141(5): 607-14 
References 35 
 
65. Rossi D, Spina V, Gaidano G. Biology and treatment of Richter syndrome. Blood. 2018; 
131(25): 2761-72 
66. Fabbri G, Khiabanian H, Holmes AB, et al. Genetic lesions associated with chronic lymphocytic 
leukemia transformation to Richter syndrome. Journal of Experimental Medicine. 2013; 
210(11): 2273-88 
67. Ben-Dali Y, Hleuhel MH, da Cunha-Bang C, et al. Richter's transformation in patients with 
chronic lymphocytic leukaemia: a Nationwide Epidemiological Study. Leukemia & Lymphoma. 
2020: 10 
68. Rossi D, Spina V, Forconi F, et al. Molecular history of Richter syndrome: origin from a cell 
already present at the time of chronic lymphocytic leukemia diagnosis. International Journal of 
Cancer. 2012; 130(12): 3006-10 
69. Jenke P, Eichhorst B, Busch R, et al. Cyclophosphamide, Adriamycin, Vincristine and 
Prednisone Plus Rituximab (CHOP-R) in Fludarabine (F) Refractory Chronic Lymphocytic 
Leukemia (CLL) or CLL with Autoimmune Cytopenia (AIC) or Richter's Transformation (RT): 
Final Analysis of a Phase II Study of the German CLL Study Group. Blood. 2011; 118(21): 
1233-4 
70. Cwynarski K, van Biezen A, de Wreede L, et al. Autologous and Allogeneic Stem-Cell 
Transplantation for Transformed Chronic Lymphocytic Leukemia (Richter's Syndrome): A 
Retrospective Analysis From the Chronic Lymphocytic Leukemia Subcommittee of the Chronic 
Leukemia Working Party and Lymphoma Working Party of the European Group for Blood and 
Marrow Transplantation. Journal of Clinical Oncology. 2012; 30(18): 2211-7 
71. Geisler C, Hansen MM, Yeap BY, et al. Chemotherapeutic options in chronic lymphocytic 
leukemia: A meta-analysis of the randomized trials. Jnci-Journal of the National Cancer 
Institute. 1999; 91(10): 861-8 
72. Langerbeins P, Bahlo J, Rhein C, et al. Ibrutinib versus placebo in patients with asymptomatic, 
treatment-naïve early stage chronic lymphocytic leukemia (CLL): Primary endpoint results of 
the phase 3 double-blind randomized CLL12 trial. (Abstract LB2602). 24th EHA Congress. 
Amsterdam, the Netherlands. June 13-16, 2019.  
73. Cheson BD, Byrd JC, Rai KR, et al. Novel targeted agents and the need to refine clinical end 
points in chronic lymphocytic leukemia. J Clin Oncol. 2012; 30(23): 2820-2 
74. Bottcher S, Ritgen M, Fischer K, et al. Minimal Residual Disease Quantification Is an 
Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic 
Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial. Journal of 
Clinical Oncology. 2012; 30(9): 980-8 
75. Kater AP, Seymour JF, Hillmen P, et al. Fixed Duration of Venetoclax-Rituximab in 
Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and 
Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. J Clin Oncol. 
2019; 37(4): 269-77 
76. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-
line therapy for chronic lymphocytic leukemia. Journal of Clinical Oncology. 2007; 25(35): 
5616-23 
77. Binet JL. Effects of chlorambucil and therapeutic decision in initial forms of chronic 
lymphocytic-leukemia (stage A): results of a randomized clinical trial on 612 patients. Blood. 
1990; 75(7): 1414-21 
78. Sylvan SE, Asklid A, Johansson H, et al. First-line therapy in chronic lymphocytic leukemia: a 
Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 
2013. Haematologica. 2019; 104(4): 797-805 
79. Leoni LM, Hartley JA. Mechanism of Action: The Unique Pattern of Bendamustine-Induced 
Cytotoxicity. Seminars in Hematology. 2011; 48(2): S12-S23 
80. Knauf WU, Lissitchkov T, Aldaoud A, et al. Bendamustine compared with chlorambucil in 
previously untreated patients with chronic lymphocytic leukaemia: updated results of a 
randomized phase III trial. British Journal of Haematology. 2012; 159(1): 67-77 
81. Keating MJ, Kantarjian H, Talpaz M, et al. Fludarabine - A new agent with major activity 
against chronic lymphocytic leukemia. Blood. 1989; 74(1): 19-25 
36 References 
 
82. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as 
primary therapy for chronic lymphocytic leukemia. New England Journal of Medicine. 2000; 
343(24): 1750-7 
83. Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus 
fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. 
Blood. 2006; 107(3): 885-91 
84. Robak T. Emerging monoclonal antibodies and related agents for the treatment of chronic 
lymphocytic leukemia. Future Oncology. 2013; 9(1): 69-91 
85. Osterborg A, Jewell RC, Padmanabhan-Iyer S, et al. Ofatumumab monotherapy in fludarabine-
refractory chronic lymphocytic leukemia: final results from a pivotal study. Haematologica. 
2015; 100(8): E311-E4 
86. Ratner M. Genentech's glyco-engineered antibody to succeed Rituxan. Nature Biotechnology. 
2014; 32(1): 6-7 
87. Cartron G, de Guibert S, Dilhuydy MS, et al. Obinutuzumab (GA101) in relapsed/refractory 
chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study. Blood. 2014; 
124(14): 2196-202 
88. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients 
who have failed fludarabine: results of a large international study. Blood. 2002; 99(10): 3554-61 
89. Osterborg A, Dyer MJ, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in 
previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H 
Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol. 1997; 15(4): 1567-74 
90. Lozanski G, Heerema NA, Flinn IW, et al. Alemtuzumab is an effective therapy for chronic 
lymphocytic leukemia with p53 mutations and deletions. Blood. 2004; 103(9): 3278-81 
91. Lundin J, Kimby E, Bjorkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal 
antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic 
lymphocytic leukemia (B-CLL). Blood. 2002; 100(3): 768-73 
92. Tam CS, O'Brien S, Plunkett W, et al. Long-term results of first salvage treatment in CLL 
patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab). Blood. 2014; 
124(20): 3059-64 
93. Thompson PA, Tam CS, O'Brien S, et al. Fludarabine, cyclophosphamide, and rituximab 
treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic 
leukemia. Blood. 2016; 127(3): 303-9 
94. Fischer K, Bahlo J, Fink AM, et al. Long-term remissions after FCR chemoimmunotherapy in 
previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016; 127(2): 
208-15 
95. Benjamini O, Jain P, Trinh L, et al. Second cancers in patients with chronic lymphocytic 
leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: 
distribution and clinical outcomes. Leukemia & Lymphoma. 2015; 56(6): 1643-50 
96. Eichhorst B, Fink AM, Bahlo J, et al. First-line chemoimmunotherapy with bendamustine and 
rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced 
chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, 
non-inferiority trial. Lancet Oncology. 2016; 17(7): 928-42 
97. Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and 
coexisting conditions. N Engl J Med. 2014; 370(12): 1101-10 
98. Thomas JD, Sideras P, Smith CIE, et al. Colocalization of X-linked agammaglobulinemia and 
X-linked immunodeficiency genes. Science. 1993; 261(5119): 355-8 
99. Bruton OC. Agammaglobulinemia. Pediatrics. 1952; 9(6): 722-8 
100. Vetrie D, Vorechovsky I, Sideras P, et al. The gene involved in X-linked agammaglobulinemia 
is a member of the SRC family of protein-tyrosine kinases. Nature. 1993; 361(6409): 226-33 
101. Pan Z, Scheerens H, Li SJ, et al. Discovery of selective irreversible inhibitors for Bruton's 
tyrosine kinase. ChemMedChem. 2007; 2(1): 58-61 
102. Chen SS, Chang BY, Chang S, et al. BTK inhibition results in impaired CXCR4 chemokine 
receptor surface expression, signaling and function in chronic lymphocytic leukemia. Leukemia. 
2016; 30(4): 833-43 
References 37 
 
103. Woyach JA, Smucker K, Smith LL, et al. Prolonged lymphocytosis during ibrutinib therapy is 
associated with distinct molecular characteristics and does not indicate a suboptimal response to 
therapy. Blood. 2014; 123(12): 1810-7 
104. de Jong J, Sukbuntherng J, Skee D, et al. The effect of food on the pharmacokinetics of oral 
ibrutinib in healthy participants and patients with chronic lymphocytic leukemia. Cancer 
Chemother Pharmacol. 2015; 75(5): 907-16 
105. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic 
lymphocytic leukemia. N Engl J Med. 2013; 369(1): 32-42 
106. Thompson PA, O'Brien S, Wierda WG, et al. Complex Karyotype is a Stronger Predictor Than 
Del(17p) for an Inferior Outcome in Relapsed or Refractory Chronic Lymphocytic Leukemia 
Patients Treated With Ibrutinib-Based Regimens. Cancer. 2015; 121(20): 3612-21 
107. Munir T, Brown JR, O'Brien S, et al. Final analysis from RESONATE: Up to six years of 
follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small 
lymphocytic lymphoma. American Journal of Hematology. 2019; 94(12): 1353-63 
108. Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naive and previously 
treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015; 125(16): 
2497-506 
109. Maddocks KJ, Ruppert AS, Lozanski G, et al. Etiology of Ibrutinib Therapy Discontinuation 
and Outcomes in Patients With Chronic Lymphocytic Leukemia. JAMA Oncol. 2015; 1(1): 80-
7 
110. Farooqui MZ, Valdez J, Martyr S, et al. Ibrutinib for previously untreated and relapsed or 
refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. 
Lancet Oncol. 2015; 16(2): 169-76 
111. O'Brien S, Jones JA, Coutre S, et al. Efficacy and Safety of Ibrutinib in Patients with Relapsed 
or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia with 17p 
Deletion: Results from the Phase II RESONATE (TM)-17 Trial. Blood. 2014; 124(21): 327 
112. Jones J, Mato A, Coutre S, et al. Evaluation of 230 patients with relapsed/refractory deletion 17p 
chronic lymphocyticleukaemia treated with ibrutinib from 3 clinical trials. British Journal of 
Haematology. 2018; 182(4): 504-12 
113. Chanan-Khan A, Cramer P, Demirkan F, et al. Ibrutinib combined with bendamustine and 
rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic 
lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-
blind, phase 3 study. Lancet Oncol. 2016; 17(2): 200-11 
114. Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as Initial Therapy for Patients with Chronic 
Lymphocytic Leukemia. New England Journal of Medicine. 2015; 373(25): 2425-37 
115. O'Brien S, Furman RR, Coutre SE, et al. Ibrutinib as initial therapy for elderly patients with 
chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, 
phase 1b/2 trial. Lancet Oncol. 2014; 15(1): 48-58 
116. Pharmacyclics. Imbruvica product monograph 2019. https://dailymed.nlm.nih.gov/dailymed/. 
Cited: 11 March, 2020.  
117. Sharman JP, Banerji V, Fogliatto LM, et al. ELEVATE TN: Phase 3 Study of Acalabrutinib 
Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) 
with Treatment-Naive Chronic Lymphocytic Leukemia (CLL). (Abstract 31). 61st ASH Annual 
Meeting and Exposition. Orlando, FL, USA. December 7-10, 2019.  
118. Dickerson T, Wiczer T, Waller A, et al. Hypertension and incident cardiovascular events 
following ibrutinib initiation. Blood. 2019; 134(22): 1919-28 
119. Mato AR, Timlin C, Ujjani C, et al. Comparable outcomes in chronic lymphocytic leukaemia 
(CLL) patients treated with reduced-dose ibrutinib: results from a multi-centre study. British 
Journal of Haematology. 2018; 181(2): 259-61 
120. Akhtar OS, Attwood K, Lund I, et al. Dose reductions in ibrutinib therapy are not associated 
with inferior outcomes in patients with chronic lymphocytic leukemia (CLL). Leuk Lymphoma. 
2019; 60(7): 1650-5 
121. Winqvist M, Andersson PO, Asklid A, et al. Long-term real-world results of ibrutinib therapy in 
patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the 
Swedish compassionate use cohort. Haematologica. 2019; 104(5): E208-E10 
38 References 
 
122. Lee R, Nayernama A, Jones SC, et al. Ibrutinib-associated Pneumocystis jirovecii pneumonia. 
American Journal of Hematology. 2017; 92(11): E646-E8 
123. Messina JA, Maziarz EK, Spec A, et al. Disseminated Cryptococcosis With Brain Involvement 
in Patients With Chronic Lymphoid Malignancies on Ibrutinib. Open Forum Infectious 
Diseases. 2017; 4(1): 4 
124. Baron M, Zini JM, Belval TC, et al. Fungal infections in patients treated with ibrutinib: two 
unusual cases of invasive aspergillosis and cryptococcal meningoencephalitis. Leukemia & 
Lymphoma. 2017; 58(12): 2981-2 
125. Lionakis MS, Dunleavy K, Roschewski M, et al. Inhibition of B Cell Receptor Signaling by 
Ibrutinib in Primary CNS Lymphoma. Cancer Cell. 2017; 31(6): 833-+ 
126. Tillman BF, Pauff JM, Satyanarayana G, et al. Systematic review of infectious events with the 
Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies. 
European Journal of Haematology. 2018; 100(4): 325-34 
127. Rogers KA, Mousa L, Zhao QH, et al. Incidence of opportunistic infections during ibrutinib 
treatment for B-cell malignancies. Leukemia. 2019; 33(10): 2527-30 
128. Long MX, Beckwith K, Do P, et al. Ibrutinib treatment improves T cell number and function in 
CLL patients. Journal of Clinical Investigation. 2017; 127(8): 3052-64 
129. Palma M, Heimersson K, Mulder T, et al. Effect of long-term ibrutinib treatment on T-cell 
number and profile in relapsed or refractory chronic lymphocytic leukemia patients: correlation 
with clinical response and tumor burden up to 4-years follow-up. (Abstract 1998). International 
Workshop on CLL, Edinburgh, UK. September 20-23, 2019.  
130. Woyach JA, Ruppert AS, Guinn D, et al. BTKC481S-Mediated Resistance to Ibrutinib in 
Chronic Lymphocytic Leukemia. Journal of Clinical Oncology. 2017; 35(13): 1437-+ 
131. Quinquenel A, Fornecker LM, Letestu R, et al. Prevalence of BTK and PLCG2 mutations in a 
real-life CLL cohort still on ibrutinib after 3 years: a FILO group study. Blood. 2019; 134(7): 
641-4 
132. Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-World Evidence - What Is It and What Can 
It Tell Us? New England Journal of Medicine. 2016; 375(23): 2293-7 
133. Mato AR, Nabhan C, Thompson MC, et al. Toxicities and outcomes of 616 ibrutinib-treated 
patients in the United States: a real-world analysis. Haematologica. 2018; 103(5): 874-9 
134. Aarup K, Enggaard L, Thomsen R, et al. Real-World Outcomes for 205 Danish Patients with 
Chronic Lymphocytic Leukemia Treated with Ibrutinib. (Abstract 1767). 61st ASH Annual 
Meeting and Exposition. Orlando, FL, USA. December 7-10, 2019.  
135. Winqvist M, Andersson PO, Asklid A, et al. 45 month follow-up of Real-World results on 
ibrutinib in relapsed/refractory CLL patients treated in the Swedish Compassionate Use 
Program (Abstract 1935). International Workshop on CLL, Edinburgh, UK. September 20-23, 
2019.  
136. Huntington S, Soulos P, Barr P, et al. Utilization and Early Discontinuation of First-Line 
Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology 
Setting in the United States. (Abstract 797). 61st ASH Annual Meeting and Exposition. 
Orlando, FL, USA. December 7-10, 2019.  
137. Tedeschi A, Burger J, Barr PM, et al. Five-year follow-up of patients recieving ibrutinib for 
first-line treatment of chronic lymphocytic leukemia. (Abstract S107). 24th EHA Congress. 
Amsterdam, the Netherlands. June 13-16, 2019.  
138. Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib-Rituximab or Chemoimmunotherapy for 
Chronic Lymphocytic Leukemia. N Engl J Med. 2019; 381(5): 432-43 
139. Shanafelt TD, Wang V, Kay NE, et al. Ibrutinib and Rituximab Provides Superior Clinical 
Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): 
Extended Follow-up from the E1912 Trial. (Abstract 33). 61st ASH Annual Meeting and 
Exposition. Orlando, FL, USA. December 7-10, 2019.  
140. Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib Regimens versus Chemoimmunotherapy 
in Older Patients with Untreated CLL. N Engl J Med. 2018; 379(26): 2517-28 
141. Moreno C, Greil R, Demirkan F, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus 
obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a 
multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019; 20(1): 43-56 
References 39 
 
142. Byrd JC, Harrington B, O'Brien S, et al. Acalabrutinib (ACP-196) in Relapsed Chronic 
Lymphocytic Leukemia. N Engl J Med. 2016; 374(4): 323-32 
143. Tam CS, Trotman J, Opat S, et al. Phase 1 study of the selective BTK inhibitor zanubrutinib in 
B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019; 134(11): 851-9 
144. Awan FT, Schuh A, Brown JR, et al. Acalabrutinib monotherapy in patients with chronic 
lymphocytic leukemia who are intolerant to ibrutinib. Blood Advances. 2019; 3(9): 1553-62 
145. Furman RR, Wierda WG, Schuh A, et al. Acalabrutinib Monotherapy in Patients with 
Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study. 
(Abstract 3039). 61st ASH Annual Meeting and Exposition. Orlando, FL, USA. December 7-10, 
2019.  
146. Kaptein A, de Bruin G, Emmelot-van Hoek M, et al. Potency and Selectivity of BTK Inhibitors 
in Clinical Development for B-Cell Malignancies. (Abstract 1871). 60th ASH Annual Meeting 
and Exposition. San Diego, CA, USA. December 1-4, 2018.  
147. Hillmen P, Brown JR, Byrd JC, et al. ALPINE: Phase III zanubrutinib (BGB-3111) versus 
ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small 
lymphocytic lymphoma (CLL/SLL). (Abstract TPS7572) Annual Meeting of the American 
Society of Clinical Oncology (ASCO), Chicago, IL, USA. May 31-Jun 4, 2019.  
148. Burger JA, Chiorazzi N. B cell receptor signaling in chronic lymphocytic leukemia. Trends in 
Immunology. 2013; 34(12): 592-601 
149. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic 
lymphocytic leukemia. N Engl J Med. 2014; 370(11): 997-1007 
150. Lampson BL, Kasar SN, Matos TR, et al. Idelalisib given front-line for treatment of chronic 
lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016; 128(2): 
195-203 
151. Weidner AS, Panarelli NC, Geyer JT, et al. Idelalisib-associated Colitis Histologic Findings in 
14 Patients. American Journal of Surgical Pathology. 2015; 39(12): 1661-7 
152. EMA. Pharmacovigilance Risk Assessment Committee. Assessment report. Procedure under 
Article 20 of Regulation No 726/2004 resulting from pharmacovigilance data 2016. 
https://www.ema.europa.eu/en/documents/variation-report/zydelig-h-c-003843-a20-1439-0023-
epar-assessment-report-article-20_en.pdf. Cited: March 20, 2020.  
153. Flinn IW, Hillmen P, Montillo M, et al. The phase 3 DUO trial: duvelisib vs ofatumumab in 
relapsed and refractory CLL/SLL. Blood. 2018; 132(23): 2446-55 
154. Brown JR. Phosphatidylinositol 3 Kinase delta Inhibitors Present and Future. Cancer Journal. 
2019; 25(6): 394-400 
155. Wei MC, Zong WX, Cheng EHY, et al. Proapoptotic BAX and BAK: A requisite gateway to 
mitochondrial dysfunction and death. Science. 2001; 292(5517): 727-30 
156. Cheng E, Wei MC, Weiler S, et al. BCL-2, BCL-X-L sequester BH3 domain-only molecules 
preventing BAX- and BAK-mediated mitochondrial apoptosis. Molecular Cell. 2001; 8(3): 705-
11 
157. Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax for Patients With Chronic 
Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II 
Pivotal Trial. J Clin Oncol. 2018; 36(19): 1973-80 
158. Jones JA, Mato AR, Wierda WG, et al. Venetoclax for chronic lymphocytic leukaemia 
progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet 
Oncol. 2018; 19(1): 65-75 
159. Birkinshaw RW, Gong JN, Luo CS, et al. Structures of BCL-2 in complex with venetoclax 
reveal the molecular basis of resistance mutations. Nat Commun. 2019; 10(1): 2385 
160. Blombery P, Anderson MA, Gong JN, et al. Acquisition of the Recurrent Gly101Val Mutation 
in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic 
Leukemia. Cancer Discov. 2019; 9(3): 342-53 
161. Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and Obinutuzumab in Patients with CLL and 
Coexisting Conditions. New England Journal of Medicine. 2019; 380(23): 2225-36 
162. Buhler A, Wendtner CM, Kipps TJ, et al. Lenalidomide treatment and prognostic markers in 
relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter 
phase-II CLL-009 trial. Blood Cancer J. 2016; 6: e404 
40 References 
 
163. Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with 
relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol. 
2006; 24(34): 5343-9 
164. Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in 
patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 2008; 111(11): 
5291-7 
165. Maffei R, Colaci E, Fiorcari S, et al. Lenalidomide in chronic lymphocytic leukemia: the present 
and future in the era of tyrosine kinase inhibitors. Crit Rev Oncol Hematol. 2016; 97: 291-302 
166. Gassner FJ, Zaborsky N, Neureiter D, et al. Chemotherapy-induced augmentation of T cells 
expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic 
lymphocytic leukemia. Haematologica. 2014; 99(5): 67-9 
167. Fink AM, Bahlo J, Robrecht S, et al. Lenalidomide maintenance after first-line therapy for high-
risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, 
phase 3 study. Lancet Haematology. 2017; 4(10): E475-E86 
168. Chanan-Khan AA, Zaritskey A, Egyed M, et al. Lenalidomide maintenance therapy in 
previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-
blind, placebo-controlled, phase 3 trial. Lancet Haematology. 2017; 4(11): E534-E43 
169. Carreras E, Dufour C, Mohty M, et al. The EBMT Handbook: Hematopoetic Stem Cell 
Transplantation and Cellular Therapies. 2019:  
170. Schetelig J, Chevallier P, van Gelder M, et al. Bridging with Idelalisib appears safe in patients 
with chronic lymphocytic leukemia (CLL) prior to allogeneic hematopoietic stem cell 
transplantation (alloHCT): A Report from the EBMT Chronic Malignancies Working Party. 
(Abstract O151) 43rd Annual Meeting of the European Society for Blood and Marrow 
Transplantation (EBMT), Marseille, France. March 26-29, 2017.  
171. Roeker LE, Brown JR, Dreger P, et al. Allogeneic Stem Cell Transplantation (alloHSCT) for 
Chronic Lymphocytic Leukemia (CLL) in the Era of Novel Agents. (Abstract 3321). 61st ASH 
Annual Meeting and Exposition. Orlando, FL, USA. December 7-10, 2019.  
172. van Gelder M, de Wreede LC, Bornhauser M, et al. Long-term survival of patients with CLL 
after allogeneic transplantation: a report from the European Society for Blood and Marrow 
Transplantation. Bone Marrow Transplantation. 2017; 52(3): 372-80 
173. National comprehensive cancer network clinical practiceguidelines in oncology. Chronic 
lymphocytic leukemia/small cell lymphoma v4.2019. https://www.nccn.org/. Cited: 10 March, 
2020.  
174. Allan N, Patel K, Mato AR, et al. Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-
Expansion Study of the Selective, Noncovalent, Reversible Bruton’S Tyrosine Kinase Inhibitor, 
Vecabrutinib, in B-Cell Malignancies. (Abstract 3041). 61st ASH Annual Meeting and 
Exposition. Orlando, FL, USA. December 7-10, 2019.  
175. Woyach J, Stephens DM, Flinn IW, et al. Final Results of Phase 1, Dose Escalation Study 
Evaluating ARQ 531 in Patients with Relapsed or Refractory B-Cell Lymphoid Malignancies. 
(Abstract 4298). 61st ASH Annual Meeting and Exposition. Orlando, FL, USA. December 7-10, 
2019.  
176. Mato A, Flinn I, Pagel J, et al. Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in 
Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-
Covalent BTK Inhibitor. (Abstract 501). 61st ASH Annual Meeting and Exposition. Orlando, 
FL, USA. December 7-10, 2019.  
177. Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell 
Leukemias and Lymphomas at the American Society Hematology Annual Meeting 2019. 
https://investor.lilly.com/news-releases/news-release-details/lilly-presents-interim-clinical-data-
loxo-305-dose-escalation. Cited: March 20, 2020.  
178. Lunning M, Vose J, Nastoupil L, et al. Ublituximab and umbralisib in relapsed/refractory B-cell 
non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2019; 134(21): 1811-20 
179. Maharaj KK, Powers J, Fonseca R, et al. Differential regulation of human T-cells by TGR-1202, 
a novel P13K delta inhibitor. (Abstract 545) AACR 107th Annual Meeting on Bioinformatics 
and Systems Biology. New Orleans, LA. April 16-20, 2016.  
References 41 
 
180. Mato A, Schuster SJ, Lamanna N, et al. A phase 2 study to assess the safety and efficacy of 
umbralisib in patients with chronic lymphocytic leukemia (CLL) who are intolerant to prior 
BTK or PI3K delta inhibitor therapy. Hematol Oncol. 2019; 37: 88-9 
181. Fraser G, Cramer P, Demirkan F, et al. Updated results from the phase 3 HELIOS study of 
ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small 
lymphocytic lymphoma. Leukemia. 2019; 33(4): 969-80 
182. Cervantes-Gomez F, Lamothe B, Woyach JA, et al. Pharmacological and Protein Profiling 
Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic 
Leukemia. Clin Cancer Res. 2015; 21(16): 3705-15 
183. Jain N, Keating M, Thompson P, et al. Ibrutinib and Venetoclax for First-Line Treatment of 
CLL. New England Journal of Medicine. 2019; 380(22): 2095-103 
184. Jain N, Keating MJ, Thompson PA, et al. Combined Ibrutinib and Venetoclax for First-Line 
Treatment for Patients with Chronic Lymphocytic Leukemia (CLL). (Abstract 34). 61st ASH 
Annual Meeting and Exposition. Orlando, FL, USA. December 7-10, 2019.  
185. Tam CS, Siddiqi T, Allan JN, et al. Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line 
Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 
Results from the MRD Cohort of the Phase 2 CAPTIVATE Study. (Abstract 35). 61st ASH 
Annual Meeting and Exposition. Orlando, FL, USA. December 7-10, 2019.  
186. Wierda WG, Siddiqi T, Flinn I, et al. Phase 2 CAPTIVATE results of ibrutinib (ibr) plus 
venetoclax (ven) in first-line chronic lymphocytic leukemia (CLL). (Abstract 7502) 60th ASH 
Annual Meeting and Exposition. San Diego, CA, USA. December 1-4, 2018.  
187. Hillmen P, Rawstron AC, Brock K, et al. Ibrutinib Plus Venetoclax in Relapsed/Refractory 
Chronic Lymphocytic Leukemia: The CLARITY Study. Journal of Clinical Oncology. 2019; 
37(30): 2722-+ 
188. Niemann CU, Dubois J, Kersting S, et al. Venetoclax and Ibrutinib for Patients with 
Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) – 15-Month Safety, Response 
and MRD Evaluation: Third Interim Analysis from the Phase II Vision HO141 Trial. (Abstract 
4292). 61st ASH Annual Meeting and Exposition. Orlando, FL, USA. December 7-10, 2019.  
189. Woyach J, Ruppert A, Perez G, et al. Alliance A041702: A Randomized Phase III Study of 
Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated 
Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL).(Abstract 
1751). 61st ASH Annual Meeting and Exposition. Orlando, FL, USA. December 7-10, 2019.  
190. von Tresckow J, Niemann C, Kater AP, et al. The GAIA (CLL13) trial: An international 
intergroup phase III study for frontline therapy in chronic lymphocytic leukemia (CLL). 
(Abstract TPS7582). 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, 
Chicago, IL, USA, June 1-5, 2018.  
191. Ding W, LaPlant BR, Call TG, et al. Pembrolizumab in patients with CLL and Richter 
transformation or with relapsed CLL. Blood. 2017; 129(26): 3419-27 
192. Mato AR, Svoboda J, Prak ETL, et al. Phase I/II Study of Umbralisib (TGR-1202) in 
Combination with Ublituximab (TG-1101) and Pembrolizumab in Patients with 
Relapsed/Refractory CLL and Richter's Transformation. (Abstract 297). 60th ASH Annual 
Meeting and Exposition. San Diego, CA, USA. December 1-4, 2018.  
193. Lemal R, Tournilhac O. State-of-the-art for CAR T-cell therapy for chronic lymphocytic 
leukemia in 2019. Journal for Immunotherapy of Cancer. 2019; 7(1): 6 
194. Gauthier J, Turtle CJ. Insights into cytokine release syndrome and neurotoxicity after CD19-
specific CAR-T cell therapy. Curr Res Transl Med. 2018; 66(2): 50-2 
195. Siddiqi T SJ, Dorritie KA, Tanya Siddiqi, Deborah M, Stephens DO, Riedell PA, Arnason JE, 
Kipps TJ, Gillenwater HH, Gong L, Dubovsky JA, Rytlewski J, Yang and Wierda WG. Rapid 
Undetectable MRD (uMRD) Responses in Patients with Relapsed/Refractory (R/R) Chronic 
Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with 
Lisocabtagene Maraleucel (liso-cel), a CD19-Directed CAR T Cell Product: Updated Results 
from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease 
Previously Treated with Ibrutinib. (Abstract 720). 61st ASH Annual Meeting and Exposition. 
Orlando, FL, USA. December 7-10, 2019.  
42 References 
 
196. Roex G, Feys T, Beguin Y, et al. Chimeric Antigen Receptor-T-Cell Therapy for B-Cell 
Hematological Malignancies: An Update of the Pivotal Clinical Trial Data. Pharmaceutics. 
2020; 12(2): 194 
197. Gill SI, Vides V, Frey NV, et al. Prospective Clinical Trial of Anti-CD19 CAR T Cells in 
Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia Shows a High 
Response Rate. (Abstract 298). 60th ASH Annual Meeting and Exposition. San Diego, CA, 
USA. December 1-4, 2018.  
198. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic 
lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic 
Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008; 
111(12): 5446-56 
199. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for Initial Evaluation, Staging, 
and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano 
Classification. Journal of Clinical Oncology. 2014; 32(27): 3059-+ 
200. Goede V, Bahlo J, Chataline V, et al. Evaluation of geriatric assessment in patients with chronic 
lymphocytic leukemia: Results of the CLL9 trial of the German CLL study group. Leuk 
Lymphoma. 2015: 1-8 
201. Sylvan SE, Rossmann E, Mozaffari F, et al. Phase I study of lenalidomide and alemtuzumab in 
refractory chronic lymphocytic leukaemia: maintaining immune functions during therapy-
induced immunosuppression. Br J Haematol. 2012; 159(5): 608-12 
202. Reynolds C, Di Bella N, Lyons RM, et al. A Phase III trial of fludarabine, cyclophosphamide, 
and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic 
leukemia. Investigational New Drugs. 2012; 30(3): 1232-40 
203. da Cunha-Bang C, Agius R, Kater AP, et al. Short-term combined acalabrutinib and venetoclax 
treatment of newly diagnosed patients with CLL at high risk of infection and/or early treatment, 
who do not fulfil IWCLL treatment criteria for treatment. A randomized study with extensive 
immune phenotyping. (Abstract 4304). 61st ASH Annual Meeting and Exposition. Orlando, FL, 
USA. December 7-10, 2019.  
204. Lampson B, Tyekucheva S, Crombie J, et al. Preliminary Safety and Efficacy Results from a 
Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously 
Untreated Chronic Lymphocytic Leukemia (CLL). (Abstract 134). 61st ASH Annual Meeting 
and Exposition. Orlando, FL, USA. December 7-10, 2019.  
 
